Health benefits of a five-day at-home modified fasting program: a randomised controlled trial

0	
4 5 6	Franziska Grundler ¹ , Quinten R. Ducarmon ^{2,3} , Alfred Holley ¹ , Marie Knufinke ^{1,4} , Selina Strathmeyer ⁵ , Steffen Heelemann ⁵ , Roland Geyer ⁵ , Borja Martinez Tellez ^{6,7} , Michael R MacArthur ⁸ , Georg Zeller ^{2,3} , Françoise Wilhelmi de Toledo ¹ , Robin Mesnage ^{1,9*}
7	
8	1 Buchinger Wilhelmi Clinic, Wilhelm-Beck-Straße 27, 88662 Überlingen, Germany
9	² Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
10	³ Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, the
11	Netherlands.
12	⁴ Laboratory of Nutrition and Metabolic Epigenetics, Department of Health Sciences and Technology, ETH Zurich,
13	Zurich, Switzerland
14	⁵ Lifespin GmbH, Am BioPark 13, 93053 Regensburg, Germany
15 16	6 Department of Nursing, Physiotherapy and Medicine and SPORT Research Group (CTS-1024), CIBIS Research Center, University of Almería, Almería, Spain.
17 18	7 Department of Medicine, Division of Endocrinology and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
19	⁸ Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton NJ 08540, USA
20	⁹ Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Life Sciences and Medicine,
21	King's College London, SE1 9NH London, UK
22	
23	* Corresponding author:
24	Dr. Robin Mesnage; robin.mesnage@buchinger-wilhelmi.com
25	
26	

27 ABSTRACT

28 Background

- 29 Fasting has been shown to be one of the most cost-effective methods to improve cardiometabolic health.
- 30 We studied a 5-day hypocaloric (~600 kcal/day) and ketogenic, modified fasting program (MFP) for at-
- 31 home interventions. We hypothesised that this MFP induces metabolic changes comparable to 5 days of
- 32 prolonged fasting (75-250kcal/day).

33 Methods

- 34 We tested the MFP in a two-arm randomised controlled trial where sixty-four healthy subjects were
- 35 randomised to MFP or control group. Serum biochemistry analyses and questionnaires allowed for
- 36 determining effects on cardiometabolic risk factors. Emotional well-being, possible side effects and
- 37 physical activity were assessed with questionnaires. Biological pathways and metabolic processes were
- 38 explored with nuclear magnetic resonance blood metabolomics and gut metagenomics analyses.

39 Results

- 40 MFP participants (n=32) experienced weight loss $(-3.1 \pm 1.1 \text{ kg})$ persisting one month after the
- 41 intervention. The MFP induced significant, but transient reductions, in systolic (-6.4 \pm 11.5 mmHg) and
- 42 diastolic (-4.4 \pm 7.7 mmHg) blood pressure, glucose levels, HbA1c and coagulation factors. The MFP led
- 43 to greater reductions in BMI (p=0.006), diastolic pressure (p = 0.009), cholesterol (p = 0.02), and LDL (p
- 44 = 0.02) in individuals at risk of cardiometabolic diseases compared to healthy individuals. Total
- 45 cholesterol, LDL-C and HDL-C levels continued decreasing during food reintroduction. The MFP also
- 46 increased emotional and physical well-being. Blood metabolomics revealed a significant decrease in
- 47 chronic inflammation markers. Shotgun metagenomics of the gut microbiome showed trends in the
- 48 changes in relative abundance of the majority of bacterial species and their genomic repertoire of
- 49 carbohydrate-active enzymes (CAZymes). This reflected a decrease in families metabolising dietary fibre
- 50 substrates and an increase in families metabolising host-derived glycan substrates. Comparing MFP
- 51 effects with a previous cohort's 5-day prolonged fasting showed similar metabolic changes.

52 Conclusion

- 53 This MFP is safe and effectively improves cardiometabolic health and emotional well-being in healthy
- 54 individuals. It offers comparable metabolic benefits to those observed during 5-day prolonged fasting in a
- 55 clinic. It is safe to be practised at home, widely accessible and compatible with individuals' everyday life.
- 56
- 57
- 58
- 59
- 60
- 61
- 62 Keywords: fasting ; cardiometabolic health ; FMD ; gut microbiome ; weight loss ; metabolomics

Introduction 63

- 64 Throughout history, humans and free living animals have regularly undergone long periods of fasting in
- response to limited food availability, during several days or weeks according to seasonal cycles ¹. and 65
- several hours while they sleep in alignment with circadian rhythms². In current times, the disruption in 66
- 67 life rhythmicity brought by the western lifestyle and the occurrence of "chronic fasting deficiency"-
- 68 when individuals do not respect physiologic fasting periods (e.g. eating at night or skipping longer
- 69 circannual fasting periods)—can be hypothesised to contribute to the development of cardiometabolic
- 70 diseases, along with other factors such as poor nutrition, exposure to toxic pollutants, decreased sleep
- 71 duration and sedentarism³. Conversely, calorie restriction and fasting are known to extend lifespan and
- 72 health span in various animal models^{1,4}.
- 73 Fasting strategies vary widely in terms of duration and frequency, as well as in caloric intake and
- macronutrient profiles ⁵. These can range from daily time-restricted eating, which reduces eating windows 74
- thus allowing fasting periods each day 6,7 , to extended fasting periods lasting up to 21 days or more 8,9 . 75
- Retaining the health benefits of fasting is often difficult once subjects return to their adipogenic 76
- 77 environment¹⁰. Incorporating fasting strategies in everyday life under online supervision could improve
- 78 compliance and increase the range of applications of fasting interventions and thus promote healthy
- longevity in the general population 11,12 . 79
- 80 We previously reported the safety, well-being and metabolic improvements in a cohort of 1422 patients
- 81 undergoing prolonged fasting programme (PF) with the Buchinger Wilhelmi protocol (75-250 kcal daily
- as fruit juice, vegetable soup and honey) lasting between 4 and 21 days under medical supervision and 82
- moderate physical activity⁸. Whether these effects persist after fasting—like after any intensive 83
- 84 nutritional intervention—depends largely on the diet during the period of food reintroduction and the
- 85 adherence to a healthy lifestyle post-intervention¹³. This underscores the necessity for new, easily accessible interventions that can be routinely implemented in daily life. To address this need, a five-day, 86
- 600-calorie ketogenic diet with restricted protein and carbohydrate intake, was designed to mimic a 5-day
- 87 88 period of PF programme in an at-home setting⁸.
- Mechanisms of fasting-induced health benefits are well understood. At the molecular level, the restriction 89
- of glucose and proteins causes the inactivation of nutrient-sensing pathways, which in return modulate 90
- adaptive cellular responses such as DNA repair, autophagy, apoptosis, and oxidative stress defence 1^{4} . 91
- 92 These mechanisms are recognized hallmarks of ageing which can partially explain the healthy longevity-
- enhancing effects of fasting¹⁵. In addition, the switch from food-derived glucose to endogenous energy 93
- 94 substrates, mainly fatty acids, triggers the production of ketone bodies which, beyond energy provision,
- signals fasting adaptations, reducing oxidative stress and inflammation⁴. The ability of the body to switch 95
- 96 between different fuel sources, such as carbohydrates and fats, is known as metabolic flexibility and can be trained by regular fasting bouts ^{16,17}. 97
- 98 Our two-arm randomised controlled trial (RCT) aimed to explore the effects of this MFP on
- 99 cardiometabolic risk factors, well-being, gut microbiome composition and functional potential as well as
- 100 the feasibility of this MFP at home. In order to understand whether the effects of our MFP can induce
- 101 hallmarks of fasting metabolism, we performed blood biochemistry, blood metabolomics and a gut
- 102 metagenomics analysis.
- 103
- 104


105 **RESULTS**


106 Study participation

107 A total of 82 healthy subjects were screened for eligibility between March 2023 and August 2023. Sixteen

- 108 subjects were excluded due to limited availability during the trial (n=10), drug intake (n=4), recent
- 109 antibiotic use (n=1), and pregnancy (n=1). Two subjects declined participation due to loss of motivation
- and an acute cold. We randomly assigned 64 participants to a group receiving the MFP or to a group of
- 111 participants who were told to continue with their usual eating behaviour and lifestyle (control group).
- 112 Recruitment, randomization and follow-up participation are summarised in the Consolidated Standards of
- 113 Reporting Trials (CONSORT) diagram (Figure 1A) together with a timeline of the programme phases
- 114 (Figure 1B).
- 115 The 22 men (34.4%) and 42 women (65.6%) who participated in this RCT were mostly Caucasian (62 out
- 116 of 64), non-smokers and moderate alcohol consumers (Table S4). There were no significant differences in
- baseline characteristics between the MFP and control group with respect to age, sex, body weight, blood
- 118 pressure and waist circumference (Table S4). Only BMI was slightly higher in the MFP group than in the
- 119 control group (Table 1).

120





- 125 group (black) at the end of the MFP period (T1), after 5 days food reintroduction (T2), or a month later
- 126 (*T3*), for major parameters reflecting the switch to the fasting metabolism, presented as changes in the
- 127 $mean \pm SD$ together with individual differences for each study individual relative to baseline (T0). The p-
- value indicates the statistical significance in a linear-mixed model where the effects are compared to the
- 129 *control group at a given timepoint* (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

130 Adverse events

- 131 We observed transient adverse events. A woman experienced brief nausea and vomiting on the second
- day of the MFP. Three participants working together in the same workplace developed symptoms on day
- 133 2 of the study, including a woman (control group) who reported nausea, vomiting, headache, dizziness
- and increased body temperature, a woman (MFP group) who reported dizziness, and a man (MFP group)
 who reported dizziness and nausea. The latter person took medication (metamizol dipyrone 500 mg for 3)
- days). All continued their participation. An environmental cause for these adverse events cannot be
- excluded, especially given that symptoms occurred in one participant of the control group.

138 Improved metabolic health in MFP as compared to controls

- 139 Participants in the MFP group experienced a variety of improvements in cardiometabolic health which
- 140 were not observed in the control group (Table 1). Body weight was decreased by 3.1 ± 1.1 kg (p = 5.8×10^{-1}
- 141 ⁸⁷) by MFP, while systolic and diastolic blood pressure were reduced by 6.4 ± 11.5 mmHg (p=0.03) and
- 142 4.4 ± 7.7 mmHg (p=0.05), respectively (Figure 1D and Table 1). Ketone bodies measured in urine with
- 143 ketone test stripes showed that participants in the MFP group entered ketosis rapidly from day 2 onwards
- 144 (Figure S1). Blood glucose and HbA1c significantly decreased by $0.71 \pm 0.69 \text{ mmol/l} (p=3.7\times10^{-57})$ and
- 145 $0.58 \pm 0.89 \text{ mmol/mol} (p=5.5 \times 10^{-7})$, respectively (Table 1), reflecting the known improvement of
- 146 glycaemic control caused by fasting.
- 147 The participants exhibited characteristic features of fasting metabolism, such as an increase in uric acid
- 148 levels ($p=6.6\times10^{-18}$), while ketonuria ($p=1.7\times10^{-29}$) and creatinine slightly increased (p=0.001) (Table 1).
- 149 There was also an increase in international normalised ratio (INR) ($p=9.6\times10^{-7}$) and partial
- thromboplastin time (PTT) (p=0.001), which altogether reflected mild anticoagulative effects
- 151 characteristic of the fasting metabolism. The increase in uric acid levels is another hallmark of fasting
- 152 metabolism which has been associated with an increased antioxidative capacity and reduced lipid
- **153** peroxidation in previous fasting studies 18 .
- 154 This MFP programme also includes a food reintroduction phase (Fig 1B), which consists of a stepwise
- reintroduction of different food items, gradually increasing the number of calories (800 to 1600 kcal per
- day during 4 days). Most of the effects observed at the end of the MFP were stable or continuously
- 157 improving after the 4 days of food reintroduction (Table 1), including further reductions in body weight,
- 158 BMI and waist circumference. LDL-C ($p=2.2\times10^{-5}$) and non-HDL-C (p=0.002) levels were significantly
- reduced compared to baseline after food reintroduction (Table 1), while they were only non-significantly
- reduced at the end of the MFP, suggesting that the MFP can have lipid metabolism-normalising effects
- 161 detectable mainly after food reintroduction.
- 162 To explore the effects of two food reintroduction strategies after fasting, participants were evenly divided:
- half received a ketogenic diet, and the other half received a non-ketogenic diet (Table S2). Limited
- 164 differences were observed between the ketogenic and standard diet groups (Table S5). Both groups
- 165 continued to excrete urinary ketone bodies consistently. Notably, the increase in PTT seen during the
- 166 modified fasting program (MFP) persisted and was amplified after ketogenic food reintroduction but not
- 167 with the standard diet (p=0.003). Conversely, the decrease in urea levels observed during MFP was

- 168 further amplified with standard food reintroduction but not with the ketogenic diet (p=0.0001).
- 169 Altogether, these findings can suggest that reintroducing food with a ketogenic diet can prolong the health
- 170 benefits of fasting by sustaining ketosis.
- 171 We investigated if the MFP-induced effects persisted after a month (Table 1). Body weight and BMI of
- the participants remained lower than baseline. Blood pressure returned to pre-intervention levels. Most of
- the parameters in these healthy subjects, which reflected beneficial changes in metabolism caused by the
- 174 MFP intervention, returned to baseline levels.
- 175
- 176 *Table 1. Biomarker or risk factor changes in the study participants.* The *p*-value indicates the statistical
- 177 significance in a linear-mixed model (individuals as random effects) where the effects of the MFP are
- 178 compared to the control (CON) group at the same timepoint (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
 179 Data as mean ± SD. # Primary endpoints.
- 180

	CON (T0)	CON (T1)	CON (T2)	CON (T3)	MFP (T0)	MFP (T1)	MFP (T2)	MFP (T3)
Clinical parameters								
# Body weight (kg)	70.1 ± 11.5	69.9 ± 11.2	69.9 ± 11.3	69.9 ± 11.3	74.0 ± 13.8	70.8 ± 13.0***	70.2 ± 13.1***	72.8 ± 14.4*
BMI (kg/m ²)	23.8 ± 3.0	23.8 ± 2.9	23.7 ± 2.9	23.7 ± 2.9	$25.4 \pm 2.7*$	24.3 ± 2.5***	24.1 ± 2.5***	$24.9 \pm 2.8*$
Waist (cm)	82.3 ± 9.7	82.1 ± 10.3	81.9 ± 10.1	80.2 ± 10.0	82.8 ± 9.4	$81.4 \pm 9.7 ***$	$79.9 \pm 9.8^{***}$	81.5 ± 9.9
# DBP (mmHg)	81.4 ± 8.7	80.4 ± 9.4	81.5 ± 9.1	81.1 ± 11.4	85.1 ± 11.4	$80.7 \pm 8.5*$	$82.9 \pm 9.1 **$	86.2 ± 10.9
# SBP (mmHg)	129 ± 13	128 ± 14	128 ± 12	128 ± 13	133 ± 16	126 ± 13*	$128 \pm 13^{*}$	132 ± 16
Resting heart rate (beats/min)	67.4 ± 10.9	67.5 ± 11.2	65.1 ± 9.7	66.3 ± 13.0	67.6 ± 11.5	67.8 ± 11.5	64.7 ± 9.7	65.9 ± 9.0
Energy metabolism								
Serum Glucose (mmol/l)	4.71 ± 0.55	4.90 ± 0.40	4.79 ± 0.45	4.77 ± 0.54	4.75 ± 0.39	4.01 ± 0.59***	$4.40 \pm 0.49 **$	4.79 ± 0.44
HbA1c (mmol/mol)	36.3 ± 3.7	36.4 ± 3.9	36.4 ± 3.9	36.6 ± 3.8	35.0 ± 2.6	34.4 ± 2.9*	34.5 ± 2.7	35.5 ± 3.0
Insulin (mIU/l)	6.91 ± 3.73	7.06 ± 3.50	6.34 ± 3.02	9.66 ± 16.04	6.50 ± 4.48	3.06 ± 1.78	4.50 ± 3.19	6.44 ± 2.51
Total Cholesterol (mmol/l)	4.98 ± 0.84	4.77 ± 0.78	4.75 ± 0.73	4.91 ± 0.81	4.98 ± 1.18	4.74 ± 1.05	$4.24 \pm 0.86^{***}$	5.16 ± 1.16*
LDL-C (mmol/l)	3.18 ± 1.00	3.05 ± 0.94	3.07 ± 0.90	3.18 ± 0.96	3.19 ± 1.07	3.05 ± 0.99	2.57 ± 0.80***	3.28 ± 1.12
HDL-C (mmol/l)	1.75 ± 0.44	1.71 ± 0.41	1.67 ± 0.41	1.59 ± 0.39	1.79 ± 0.51	$1.64 \pm 0.50*$	1.55 ± 0.41**	1.69 ± 0.48
Non-HDL-C (mmol/l)	3.22 ± 0.97	3.06 ± 0.93	3.07 ± 0.87	3.32 ± 0.95	3.19 ± 1.10	3.09 ± 0.89	$2.68 \pm 0.79 **$	3.46 ± 1.08
LDL/HDL (ratio)	1.99 ± 0.91	1.94 ± 0.88	2.01 ± 0.91	2.17 ± 0.95	1.97 ± 0.98	2.05 ± 1.06	1.82 ± 0.92	2.12 ± 1.02
TG (mmol/l)	1.02 ± 0.45	0.92 ± 0.38	0.91 ± 0.38	1.02 ± 0.56	1.00 ± 0.56	0.91 ± 0.20	0.88 ± 0.29	1.14 ± 0.75
Acetoacetate in urine morning (mg/dl)	1.25 ± 2.20	0.65 ± 1.70	0.54 ± 1.57	1.25 ± 3.23	1.29 ± 3.87	$42.8 \pm 27.0^{***}$	$14.8 \pm 15.6^{***}$	1.11 ± 3.20
Acetoacetate in urine evening (mg/dl)	1.07 ± 2.09	0.50 ± 1.53	0.52 ± 1.55	1.96 ± 7.62	0.78 ± 1.84	$21.8 \pm 16.4 ***$	$6.15 \pm 9.20 ***$	0.93 ± 3.11
TSH (mE/l)	2.37 ± 1.58	1.97 ± 1.43	2.02 ± 1.27	2.44 ± 2.60	2.32 ± 1.13	1.65 ± 0.86	1.74 ± 0.81	2.04 ± 1.02
Inflammatory parameters								
CRP (mg/l)	1.54 ± 1.46	1.20 ± 1.20	1.02 ± 1.02	3.02 ± 7.89	1.23 ± 1.94	1.72 ± 2.19	1.33 ± 1.96	1.12 ± 1.92
ESR (mm/h)	4.19 ± 3.40	4.38 ± 4.42	3.44 ± 2.78	5.91 ± 7.90	3.19 ± 2.91	3.59 ± 6.02	2.44 ± 1.05	4.03 ± 4.76
TNF alpha (pg/ml)	5.75 ± 1.42	6.00 ± 1.75	5.66 ± 1.33	6.60 ± 2.67	5.84 ± 1.63	5.80 ± 1.34	5.62 ± 1.10	$5.65 \pm 1.27 **$
Kidney function								
Creatinine (µmol/l)	67.5 ± 10.4	67.2 ± 10.2	68.6 ± 11.3	66.9 ± 10.9	69.2 ± 12.6	73.5 ± 14.3**	70.0 ± 13.4	67.2 ± 11.3
GFR (ml/min)	104 ± 14	104 ± 14	102 ± 16	104 ± 15	99.6 ± 17.4	97.0 ± 16.2	101 ± 16	104 ± 16
Urea (mmol/l)	5.34 ± 1.43	5.00 ± 1.27	5.06 ± 1.26	5.14 ± 1.52	4.97 ± 1.25	$3.52 \pm 1.03^{***}$	$3.80 \pm 1.11 **$	5.23 ± 1.48
Uric Acid (µmol/l)	277 ± 79	273 ± 66	275 ± 66	285 ± 85	293 ± 72	$433 \pm 131^{***}$	$341 \pm 87 **$	287 ± 53
Liver function								
Alkaline phosphatase (U/l)	64.3 ± 20.3	62.0 ± 19.8	62.0 ± 19.5	65.7 ± 20.5	64.2 ± 22.7	60.2 ± 21.6	$56.8 \pm 18.3 **$	63.0 ± 23.2
GOT (U/l)	17.8 ± 6.8	17.2 ± 7.0	16.5 ± 6.3	19.0 ± 7.3	16.9 ± 5.4	$26.7 \pm 15.8^{***}$	19.7 ± 8.9	18.6 ± 9.3
GPT (U/l)	23.9 ± 9.9	22.6 ± 9.9	21.4 ± 8.9	23.8 ± 9.9	22.0 ± 5.7	$26.2 \pm 12.2^{**}$	$24.8 \pm 11.9 \ast$	20.9 ± 9.5
Gamma GT (U/l)	20.8 ± 14.8	19.6 ± 12.7	18.3 ± 13.1	19.8 ± 12.2	19.0 ± 10.8	16.3 ± 8.7	14.1 ± 6.7	$21.0\pm15.1*$
Redox parameters								
ACL Lipid-soluble Antiox Cap (µmol/l)	42.2 ± 14.8	38.7 ± 10.5	39.2 ± 9.7	40.1 ± 9.7	38.3 ± 10.9	35.6 ± 9.6	33.4 ± 7.2	38.7 ± 10.9

ACU Urate-independent Antiox Cap (µmol/l)	82.4 ± 26.5	88.8 ± 28.6	79.7 ± 19.2	81.7 ± 21.3	80.2 ± 23.4	$71.6\pm20.0*$	80.4 ± 15.6	69.4 ± 15.7
Plasma Lipid Peroxides (µmol/l)	411 ± 245	392 ± 239	329 ± 246	363 ± 228	387 ± 198	323 ± 215	335 ± 228	369 ± 233
Blood cells								
Erythrocytes (Mio/µl)	4.57 ± 0.33	4.48 ± 0.38	4.46 ± 0.38	4.49 ± 0.33	4.71 ± 0.40	$4.76 \pm 0.37 **$	4.60 ± 0.37	4.67 ± 0.41
Hematocrit (%)	40.9 ± 3.0	39.9 ± 3.1	39.6 ± 3.1	40.0 ± 2.5	41.2 ± 3.2	$41.2 \pm 2.9*$	39.8 ± 2.9	41.1 ± 3.1
Hemoglobin (g/dl)	13.7 ± 1.0	13.5 ± 1.2	13.5 ± 1.1	13.6 ± 1.0	14.0 ± 1.2	$14.2 \pm 1.1*$	13.7 ± 1.1	13.9 ± 1.0
Leukocytes (Tsd./µl)	6.37 ± 1.46	5.83 ± 1.43	5.75 ± 1.43	6.32 ± 2.30	5.72 ± 2.23	4.97 ± 1.41	4.60 ± 1.63	5.53 ± 1.50
MCH (pg)	30.0 ± 1.4	30.3 ± 1.4	30.3 ± 1.4	30.4 ± 1.5	29.8 ± 1.6	29.9 ± 1.6	29.8 ± 1.7	29.9 ± 1.8
MCHC (g/dl)	33.5 ± 1.1	33.9 ± 1.1	34.1 ± 0.8	34.1 ± 1.1	34.0 ± 1.0	34.4 ± 0.9	34.4 ± 0.9	$33.9\pm0.9^{**}$
MCV (fl)	89.6 ± 3.6	89.3 ± 3.4	88.9 ± 2.8	89.1 ± 3.6	$87.6\pm4.8^*$	86.8 ± 4.1	86.6 ± 4.0	$88.4 \pm 4.4^{**}$
MPV (fl)	10.7 ± 0.7	10.6 ± 0.6	10.8 ± 0.8	11.0 ± 0.8	10.8 ± 0.7	10.9 ± 0.7	11.0 ± 0.7	10.8 ± 0.7
P-LCR (%)	30.4 ± 5.5	29.5 ± 4.6	30.7 ± 6.6	32.4 ± 6.7	30.6 ± 4.7	32.4 ± 6.0	$33.3 \pm 5.1 ***$	31.7 ± 5.6
PDW (fl)	12.6 ± 1.4	12.3 ± 1.1	12.7 ± 1.8	13.1 ± 1.8	12.6 ± 1.2	13.1 ± 1.6	13.3 ± 1.3*	12.9 ± 1.6
Platelets (Tsd./µl)	256 ± 62	254 ± 58	251 ± 63	254 ± 61	246 ± 55	230 ± 63	226 ± 56	250 ± 75
RDW (%)	12.9 ± 0.7	12.9 ± 0.8	12.9 ± 0.7	12.7 ± 0.6	12.9 ± 0.9	$12.5 \pm 0.8 **$	$12.6 \pm 0.8*$	$13.0 \pm 0.8 **$
Coagulation								
INR	1.00 ± 0.05	1.03 ± 0.06	1.00 ± 0.06	1.02 ± 0.07	0.99 ± 0.07	1.08 ± 0.06***	1.04 ± 0.06***	1.00 ± 0.06
PTT (sec)	30.5 ± 2.3	30.9 ± 2.1	30.7 ± 2.1	30.4 ± 2.2	31.4 ± 2.9	$32.8 \pm 3.6^{**}$	$33.2 \pm 3.7 ***$	31.2 ± 2.9
Quick (%)	101 ± 8	96.5 ± 8.6	101 ± 10	98.7 ± 9.5	102 ± 11	$90.1 \pm 6.9^{***}$	$94.3 \pm 8.5^{***}$	100 ± 9
Electrolytes								
Calcium (mmol/l)	2.32 ± 0.08	2.34 ± 0.07	2.34 ± 0.09	2.36 ± 0.09	2.33 ± 0.09	2.36 ± 0.09	2.35 ± 0.07	2.38 ± 0.12
Magnesium (mmol/l)	0.84 ± 0.05	0.82 ± 0.05	0.83 ± 0.05	0.83 ± 0.06	0.84 ± 0.06	0.84 ± 0.06	$0.81 \pm 0.07*$	0.82 ± 0.06
Potassium (mmol/l)	4.25 ± 0.23	4.14 ± 0.18	4.33 ± 0.23	4.24 ± 0.26	4.34 ± 0.45	4.19 ± 0.37	4.28 ± 0.33	4.34 ± 0.44
Sodium (mmol/l)	139 ± 2	139 ± 2	140 ± 2	140 ± 2	140 ± 3	138 ± 3	$139 \pm 2*$	140 ± 2

181

182 Effects on individuals at risk of chronic diseases.

We evaluated whether the MFP caused even larger benefits for the health of individuals with risk factors of cardiometabolic disease (Table 2). Subjects with BMI >25 kg/m² showed a stronger reduction in BMI than those with BMI < 25 (p = 0.006). Systolic and diastolic blood pressure were reduced by 0.94 ± 8.7

mmHg and 0.31 ± 6.37 mmHg in healthy subjects, respectively, but by 9.32 ± 11.8 mmHg and -7.31 ± 10.7

187 7.34 mmHg in at-risk individuals. This reached statistical significance for diastolic (p = 0.009) but not

188 systolic (p= 0.08) blood pressure. Cholesterol and LDL levels also significantly decreased in participants

189 with elevated baseline values: cholesterol >200 mg/dl dropped by 19.7 mg/dl (p = 0.02), and LDL >130

190 mg/dL decreased by 16.8 mg/dl (p = 0.02).

191

192 We investigated whether the amount of 600 kcal in this program would impact individuals with different

energy requirements. First, we calculated the resting energy expenditure (REE) of every participant using

the validated Oxford equation ¹⁹. After that, we divided the 32 participants included in the MFPgroup into

- 195 tertiles and compared individuals with high REE (highest tertile) vs individuals with low REE (lowest tertile). Individuals with high REE lost more weight than those with low REE (-3.9 kg vs -1.8 kg,
- tertile). Individuals with high REE lost more weight than those with low REE (-3.9 kg vs -1.8 kg, respectively, $p = 5.5 \times 10$ \square). However, there were no differences in the metabolic changes in systolic
- respectively, $p = 5.5 \times 10 \square \square$). However, there were no differences in the metabolic changes in systolic or diastolic blood pressure, uric acid levels, or in parameters of coagulation, glucose, or lipid metabolism,
- such as total cholesterol, LDL, HDL cholesterol, or GGT (all p > 0.05). This suggests that while
- individuals with higher REE lose more weight due to a greater negative calorie balance, the 600 kcal per
- 201 day provided in this program is able to produce similar metabolic benefits in people with lower REE. This
- implies that the cardiometabolic benefits of fasting in regulating glucose and lipid metabolism may be
- 203 independent of the fasting induced weight loss.

205 Table 2. Posthoc analysis of changes in the levels of risk factors for individuals at risks of chronic

disease. Not enough individuals had poor glycemic control (serum glucose level over 100 mg/dL or
 HbA1c levels over 5.7%). The p-values are from an independent t-test.

Parameter	n	Delta T1 – T0	р
BMI (kg/m^2)			0.006
>25	15	-1.22 ± 0.20	
<25	17	-0.91 ±- 0.37	
SBP (mmHg)			0.08
>120	23	-9.32 ± 11.8	
<120	8	-0.94 ± 8.7	
DBP (mmHg)			0.009
>80	18	-7.31 ± 7.34	
<80	13	-0.31 ± 6.37	
Cholesterol (mg/dl)			0.02
>200	12	-19.7 ± 18.0	
<200	20	-3.4 ± 17.2	
LDL (mg/dl)			0.02
>130	12	-16.8 ± 21.5	
<130	20	$+1.7\pm16.1$	
HDL (mg/dl)			0.1
>60	20	-6.9 ± 7.5	
<60	12	-3.1 ± 5.6	

208

209

210 Well-being, symptoms and lifestyle

211 Participants answered daily questionnaires to assess their well-being, possible side effects, and lifestyle 212 factors throughout the study. The MFP increased emotional and physical well-being, as well as quality of 213 life evaluated using the WHO-5 index (Table 3). Energy level was higher in the MFP group after food 214 reintroduction in comparison to baseline, but they returned to baseline after a month. Participants in the 215 MFP group reported significantly higher levels of anxiety, cravings, headache, insomnia, and muscle weakness at baseline in comparison to the control group. Although it is unclear whether these differences 216 217 existed prior to randomization, it is likely that the elevated anxiety symptoms were linked to concerns about undergoing the fasting experience. These symptoms rapidly normalised during the early days of the 218 219 MFP and were no different from those experienced by the control group during the MFP and the 220 subsequent food reintroduction. Hunger or sleep quality was not different between the two groups. Note

that these findings are based on self-reported measures, which may limit their robustness.

Table 3. Well-being, symptoms and physical activity – questionnaires. The p-value indicates if the

changes in time for a given parameter are different between the MFP group and the control (CON)

group. The p-value indicates the statistical significance in a linear-mixed model where the effects of the

- 225 *MFP* are compared to the control group at a given timepoint (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
- 226 Some questions were asked daily (& symbol) while some were only asked at a given timepoint. All scales

are interpreted from 0 (minimum intensity) to 10 (maximum intensity) Data as mean ± SD for given
timepoints.

	CON (T0)	CON (T1)	CON (T2)	CON (T3)	MFP (T0)	MFP (T1)	MFP (T2)	MFP (T3)
EWB (0-10) &	7.47 ± 1.88	7.53 ± 2.06	7.30 ± 2.12	7.63 ± 1.43	6.84 ± 2.50	$8.06 \pm 1.53*$	8.28 ± 1.58	7.63 ± 1.73
WHO (0-100)	27.5 ± 9.4	24.8 ± 8.7	23.4 ± 9.3	24.7 ± 8.2	25.9 ± 9.1	22.4 ± 10.2	18.5 ± 5.5	23.6 ± 10.3
Physical activity (0-10)	6.19 ± 2.49	5.72 ± 2.11	5.73 ± 2.45	5.76 ± 2.37	6.03 ± 2.09	5.77 ± 2.54	5.90 ± 2.73	5.37 ± 2.72

Physical activity (hours/day) &	3.64 ± 3.46	3.30 ± 2.94	3.25 ± 3.18	3.10 ± 2.82	4.39 ± 3.88	3.45 ± 3.04	4.75 ± 4.25	3.43 ± 3.32
PWB (0-10) &	7.31 ± 1.84	7.47 ± 1.87	7.37 ± 1.99	7.53 ± 1.63	6.78 ± 2.43	7.77 ± 1.78**	8.28 ± 1.71	7.40 ± 2.01
IPAQ (MET-min/week)	3961 ± 3844	5916 ± 8170	2985 ± 4002	4491 ± 7961	2886 ± 2165	20.41 ± 21.66	2602 ± 3384	5323 ± 7932
Backache (0-10) &	1.12 ± 1.77	0.88 ± 1.56	0.60 ± 1.54	1.03 ± 1.76	2.09 ± 2.80	1.81 ± 2.70	1.03 ± 1.68	1.43 ± 2.21
Energy level (0-10) &	6.84 ± 2.03	7.25 ± 1.80	7.03 ± 1.96	7.10 ± 1.65	6.41 ± 2.37	7.10 ± 2.23	$8.28 \pm 1.71 **$	7.70 ± 1.88
Fatigue (0-10) &	4.09 ± 2.96	3.44 ± 2.08	2.73 ± 2.70	3.45 ± 2.11	4.69 ± 3.04	$3.29\pm2.81*$	1.52 ± 2.25	$1.97 \pm 2.14 **$
Fear (0-10) &	0.44 ± 0.88	0.06 ± 0.25	0.23 ± 0.77	0.17 ± 0.54	1.06 ± 1.83	0.35 ± 0.80	$0.07 \pm 0.37 **$	0.30 ± 0.84
Flatulence (0-10) &	2.56 ± 2.71	1.69 ± 2.18	1.40 ± 2.04	1.87 ± 1.98	2.56 ± 2.96	1.55 ± 2.68	1.48 ± 2.29	1.70 ± 2.31
Headache (0-10) &	1.16 ± 2.62	0.50 ± 1.16	0.33 ± 1.03	0.62 ± 1.12	2.56 ± 3.16	$0.23 \pm 0.62^{***}$	0.34 ± 1.34	$0.30 \pm 1.06*$
Hunger (0-10) &	3.06 ± 2.94	1.69 ± 1.79	1.63 ± 2.17	2.03 ± 2.06	3.97 ± 2.92	3.06 ± 2.76	2.38 ± 2.77	2.83 ± 2.87
Indigestions (0-10) &	1.31 ± 2.51	1.06 ± 2.26	0.37 ± 0.72	0.83 ± 1.61	1.56 ± 2.60	1.16 ± 2.28	0.97 ± 2.24	0.70 ± 2.04
Insomnia (0-10) &	1.50 ± 1.88	1.27 ± 1.81	1.41 ± 1.74	2.41 ± 2.28	$2.62 \pm 2.34*$	2.34 ± 2.47	1.23 ± 2.01	$2.07 \pm 2.13*$
Myasthenia (0-10) &	1.16 ± 1.80	0.75 ± 1.68	0.53 ± 1.36	0.45 ± 0.74	2.31 ± 3.17	1.94 ± 2.24	0.83 ± 1.56	0.93 ± 1.53
Ravenous appetite (0-10) &	2.12 ± 2.66	0.94 ± 1.76	0.63 ± 1.33	1.17 ± 2.02	$3.59\pm3.05*$	2.29 ± 2.83	2.07 ± 2.52	2.53 ± 2.66
Sensation of cold (0-10) &	0.28 ± 0.68	0.44 ± 1.83	0.40 ± 1.83	0.80 ± 1.56	$1.94 \pm 2.97 **$	$0.06 \pm 0.25^{**}$	0.41 ± 1.21	$0.30 \pm 0.92^{**}$
Sleep quality (0-10) &	3.03 ± 2.57	1.85 ± 1.99	2.10 ± 2.40	3.52 ± 2.61	3.53 ± 2.33	3.09 ± 2.83	2.07 ± 2.79	3.07 ± 2.96
Backache (0-10)	2.03 ± 1.84	0.88 ± 1.66	0.83 ± 1.7	1.31 ± 1.67	$3.78 \pm 2.89^{**}$	1.77 ± 2.31	1.6 ± 2.25	$2.1 \pm 2.35*$
Heartburn (0-10)	0.69 ± 1.35	0.19 ± 0.64	0.23 ± 0.5	0.28 ± 0.75	1.44 ± 2.23	0.58 ± 1.48	0.3 ± 0.75	0.37 ± 0.76
Joint pain (0-10)	1.56 ± 2.18	1.16 ± 2.29	0.73 ± 1.68	0.79 ± 1.76	2.34 ± 2.68	1.32 ± 2.37	1.03 ± 1.63	1.6 ± 2.21
Muscle (0-10)	1.5 ± 1.65	0.75 ± 1.48	0.67 ± 1.58	0.72 ± 1.28	2.0 ± 2.29	2.0 ± 2.52	1.17 ± 1.76	1.13 ± 1.68
Stomach ache (0-10)	1.91 ± 2.54	0.62 ± 1.48	0.4 ± 0.81	0.86 ± 2.08	1.69 ± 2.04	0.81 ± 1.47	1.0 ± 1.88	1.0 ± 1.74
Stress (0-10)	4.44 ± 1.93	3.59 ± 2.15	3.93 ± 2.16	3.79 ± 2.29	$5.5\pm2.16^{\ast}$	4.03 ± 2.51	3.97 ± 2.51	4.2 ± 2.23
PSQI (0-20)	7.59 ± 2.75	6.66 ± 2.91	5.73 ± 2.56	6.16 ± 2.92	8.50 ± 3.31	7.68 ± 3.02	6.33 ± 2.54	6.71 ± 2.67

230

231

232 Serum metabolomics reflects remodelling of energy metabolism

233 NMR metabolomics revealed that the MFP caused marked metabolic changes, which persisted during the

food reintroduction and returned to baseline after a month (Figure 2). We observed that concentrations of

235 24 metabolites were significantly decreased in the MFP in comparison to the control group, and that 9


metabolites were increased. In line with expectations from metabolic switching, strong increases were

237 observed for the ketone bodies acetoacetic acid and 3-hydroxybutyric acid after the MFP. Strongly

decreased metabolites include amino acids (i.e., proline, alanine, glutamine, glycine, methionine, lysine,

serine, threenine, histidine). Other notably decreased metabolites include glycoprotein acetyls A, a known

biomarker of chronic inflammation ²⁰. Altogether, this serum metabolomics analysis reflected a strong
 metabolic remodelling caused by the fasting intervention, but also a return to baseline after a month.



242



245 Figure 2. Serum metabolomics analysis of the effects of the MFP on serum metabolite composition. A: 246 Heatmap showing the changes in the levels of metabolites between the MFP group and the control group 247 at different timepoints. The colour scale shows the estimate of the difference between the MFP group and 248 the control group in a linear mixed model with individuals as random effects. The p-value resulting from 249 these models was adjusted for multiple comparisons using the Benjamini-Hochberg procedure (*, p < 1250 0.05; **, p < 0.01; ***, p < 0.001). **B**: Principal Component Analysis (PCA) shows the structure of the 251 variance between these groups and timepoints. The PCA was done for all samples together, but the 252 grouping of samples are visualised facetted for the sake of clarity. C: Time trajectory for the abundance 253 of 6 metabolites with the lowest p-values.

254

255 Shotgun metagenomics reveals foraging of host-derived substances

256 Changes in the gut microbiota were investigated by performing shotgun metagenomics on participants'

257 faecal samples. Both alpha diversity analysed with the Shannon index (Figure 3A) and beta diversity


analysed with Bray-Curtis dissimilarity remained unchanged (Figure 3B). Limited changes were observed 258

with only 11 species having their relative abundance statistically significantly changed at T1 of MFP

versus T1 of controls (as assessed by mOTUs, Figure 3C). No changes were observed at T3 compared toT0, indicating that the effects on the gut microbiota were transitory.

Changes in energy metabolism in the gut microbiota were even clearer. We analyzed substrate preference 262 derived from CAZyme abundances quantified from metagenomes²¹. A total of 52 CAZymes had their 263 264 abundance significantly changed at T1 of MFP versus T1 of controls, but none were persistently changed at T3. This reflected a transient reduction in the abundance of CAZymes that metabolise dietary fibre 265 266 concomitant with an increase in CAZymes involved in host-derived glycosaminoglycan foraging. Gene-267 set enrichment analysis (GSEA) to evaluate substrate enrichments suggested that the gut microbiome 268 switched metabolism and started foraging host-derived substances during the MFP intervention (Figure 269 3H).

270



272 Figure 3. Changes in faecal microbiota composition and function. A: Alpha diversity was computed as

273 Shannon diversity. B: The Principal Coordinate Analysis (PCoA) of microbial communities is based on

- 274 Bray-Curtis dissimilarities, coloured by timepoints and faceted by study arms. C: Individual changes in
- abundance for the 11 bacteria species with the p-values <0.05 in the evaluation of the effect of the MFP
- 276 (*T1 vs T0*). *D. All CAZyme families were additionally subjected to gene-set enrichment analysis (GSEA)*
- 277 to evaluate substrate enrichments (p-values are indicated as start symbols, p<0.05; p<0.01; p<0.01; p<0.01; p<0.01; p<0.01; p<0.01; p<0.01; p>0.01; p>0.
- **278** p<0.001). Generalized fold changes were calculated using linear mixed models (LMMs) with random
- 279 *intercepts for the individuals.*

280

281 Comparison with 5 days of prolonged fasting

We compared the effects of the MFP to the effects of 5 days of PF according to the Buchinger Wilhelmi protocol (75 - 250 kcal/day). In order to allow for fair comparisons between groups, we matched each of

the 32 participants from the MFP group to individuals with similar sex, age, blood pressure, triglycerides,

285 BMI, waist circumference from a total of 400 patients who performed 5 days of fasting in the Buchinger

286 Wilhelmi clinic in 2016⁸. Effect sizes of the MFP or 5 days of fasting were comparable for most clinical

parameters (Figure 4A and Table S6). Effects of the MFP were slightly more pronounced than 5 days of

288 prolonged fasting for the changes in the anticoagulative effects and the glucose levels. The latter is related

to the glucose content of the supplementation, higher in PF and then MFP. Altogether, this shows that the

290 MFP has comparable beneficial metabolic effects to PF.

291 We compared the directionality of the changes in gut microbiota composition with the changes caused by

292 PF we observed in another study 22 . The changes induced during PF are comparable to those induced by

the MFP (Figure 4B), as shown by the statistically significant correlation between generalized fold


changes for each mOTU measured in both interventions (Figure 4D). The changes in CAZy families were

highly correlated (Figure 4E) and thus comparable to those observed during PF (Figure 4B). Gene-set

enrichment analysis (GSEA) suggested that the gut microbiome switched metabolism in a comparable

way to what is observed during PF (Figure 4F).

298





300 Figure 4. Metabolic changes caused by the MFP were comparable to those of a 5-day prolonged

fasting. *A. Comparison of the effect size estimated from the effects of 5-day MFP in comparison to the*

302 control group at T1 for parameters showing statistically significant changes in their levels at T1. These

303 effects are also compared to 5 days of prolonged fasting in 32 individuals matched based on their age,

- 304 sex, body weight and triglyceride levels out of 400 participants who fasted according to the Buchinger Wilhelmi fasting programme (250 kcal/day) in 2016. B: Dot plot shows fold changes in differential
- 305 306 abundance in microbiota composition before and after the MFP intervention in comparison to PF in
- 307 another study. C: Differential CAZyme family abundance in comparison to PF in another study. D:
- 308 Correlations between fold changes in relative abundance for microbiota composition. E: Correlations
- 309 between fold changes for CAZyme family abundance. F. All CAZyme families were additionally subjected
- 310 to gene-set enrichment analysis (GSEA) to evaluate substrate enrichments (p-values are indicated as start
- symbols, * p < 0.05; ** p < 0.01; *** p < 0.001). Parameters are ordered by MFP effect sizes. Statistical 311
- 312 significance is indicated with crossed circles (p < 0.05).
- 313
- 314

315 DISCUSSION

316 Large research efforts are currently undertaken to find pharmacological and non-pharmacological

- 317 interventions for maintaining body weight and blood pressure within recommended limits, in order to
- 318 reduce the high incidence of chronic metabolic diseases such as type 2 diabetes or coronary heart disease
- 319 23 . The possibility to modulate cardiovascular risk factors triggers the need for proactive healthcare policy
- planning²⁴. The MFP evaluated in the present RCT demonstrates that short fasting periods performed at 320
- home are an effective strategy for reducing body weight and improving the cardiometabolic profile. 321

322 Compared to pharmacological approaches for weight loss and metabolic normalisation, such as GLP-1 agonists ²⁵, fasting strategies generally present with only mild side effects, particularly when conducted 323 under professional supervision, either in specialised institutions or for shorter periods through online 324 platforms, as is the case of MFP⁸. Unlike GLP-1 agonists, which are associated with significant costs²⁶. 325 non-pharmacological strategies like MFP empowers individuals to explore and manage on their own 326 dietary strategies enhancing a sense of self-efficacy and safety ²⁷. The alternance of MFP with a normal 327 328 diet triggers well-being and diminishes cravings often associated with continuous caloric restriction. MFP offers health benefits and is compatible with daily life²⁸. Short and periodically repeated interventions 329 330 also prevents from developing with its deleterious effects on the immune system and wound healing 29 . 331 Nevertheless, the risk of falling back into old lifestyle habits that led to poor metabolic health cannot be

332 fully eliminated.

333 The mechanisms through which the MFP intervention may confer health benefits seem to be multifaceted 334 and deeply interconnected. The loss of body weight by itself could explain a decrease in chronic

inflammation ³⁰. The clinical and metabolic changes caused by the MFP were comparable to those 335

- 336 observed after PF (i.e. total of 5 days of fasting at 250 kcal/day). The changes caused by the metabolic
- 337 shift into ketosis fasting are known to contribute to beneficial changes in nutrient-sensing signalling
- pathways ^{31,32}, which play crucial roles in regulating cellular processes related to metabolism, growth, 338
- autophagy, stem cell-based regeneration and ultimately longevity ¹⁴. Therefore, by modulating these 339
- pathways, our MFP holds substantial potential for enhancing public health. 340
- 341 A single cycle of the MFP showed maintenance of weight loss after a month in predominantly normal
- 342 weighted individuals, while other parameters returned to baseline. The easy implementation makes it a
- 343 promising candidate for multiple-cycle programs, potentially mirroring the enhanced outcomes seen with
- 344 Fasting Mimicking Diets (FMD). In humans, three cycles of a monthly 5-day FMD in a RCT involving
- 345 100 healthy subjects resulted in weight loss of on average 2.6 ± 2.5 kg, decreased BMI, total body fat,

trunk fat and reduced waist circumference ³³. It also reduced the need for medication and improved
glycaemic control in primary care for type 2 diabetes ³⁴. A study involving 24 healthy volunteers
confirmed the glucose-lowering effect of a 5-day FMD and also demonstrated reductions in IGF-1
alongside improved insulin sensitivity ³⁵. A recent study even showed that three cycles of FMD had the
potential of slowing down markers of biological ageing ³⁶. Longer follow-up including different
frequencies of MFP use will be needed to understand whether this MFP can be used to treat chronic

diseases.

Our study shows that the MFP is an effective method to address risk factors for cardiometabolic diseases.A main strength of our study is the joint collection of patient blood markers, metagenomic and

355 metabolomic data in a longitudinal design surveyed under randomised controlled clinical conditions. This 356 helped us demonstrate that this MFP can exert beneficial health effects by eliciting mechanisms which are

357 known hallmarks of the fasting metabolism. We even noted that participants in the MFP group with

higher baseline values above the norm ranges experienced more significant improvements in metabolicparameters compared to those whose values were within the normal range. This was suggested in another

- 359 parameters compared to those whose values were within the normal range. This was suggested in another 360 study where metabolic markers like fasting glucose, triglycerides, CRP, and cholesterol levels, which
- 361 were within the normal range at baseline, did not show significant changes after three cycles of FMD in a
- 362 randomised comparison ³³. The same is true for the PF⁸, showing that at-risk individuals may benefit
- 363 more from the intervention. Another strength of our program is that participants received educational
- material to improve their lifestyle including instructions to do more physical activity. It can also be seen
- as a limitation, because even if the control group received similar advice and could be used todifferentiate the effects of the MFP from the effects of the accompaniment, it is not always practical to
- 367 disentangle the contribution of the numerous factors which compose such a lifestyle intervention. Other
- 368 limitations include the focus on individuals who were mostly metabolically healthy, making it
- 369 challenging to predict the potential benefits or difficulties that might arise in patients with underlying
- 370 conditions. Therefore, further research is needed to explore the effects of MFP in patients with metabolic
- 371 conditions such as hypertension or type 2 diabetes, or fatty liver disease chronic diseases.

372 This new programme is in line with the need for lifestyle interventions which substantially decrease

healthcare costs ^{37,38}. At-home interventions are accessible to a broad population, and are compatible with

individuals' daily lives, thereby increasing the likelihood for long-term adherence. This could be the casewhen individuals are confined at home in isolation such as during the Coronavirus-19 disease (COVID-

376 19) pandemic ^{39,40} or other reasons.

In conclusion, the results of this RCT show that the MFP is an effective intervention for reducing body
weight, lowering blood pressure and inducing a metabolic switch to ketosis thus inducing similar
beneficial effects than those observed in other fasting interventions. The improvements in cardiovascular

- and metabolic risk factors, especially in subjects with elevated baseline levels of these markers, are of
- 381 significant value for non-pharmacological public health strategies.
- 382

383 Future investigations should prioritise the study of at-risk patient groups to understand the efficacy of

- 384 MFP in reducing lifestyle-related diseases, assess long-term effects, and explore the fasting-like effects to 385 gain insight into its broader preventive and therapeutic benefits for promoting health and longevity.
- 386
- 207
- 387
- 388

389 MATERIALS AND METHODS

390 Subjects

391 The Fastreset study was designed as a RCT with two parallel study arms. Subjects were randomised either 392 to five days of MFP followed by four days of food reintroduction or to their usual diet (Figure 1B). The 393 study protocol was approved by the Ethics Committee of the Medical Association of Baden-Württemberg, 394 Stuttgart, Germany (approval number: F-2023-014). The study was registered at ClinicalTrials.gov 395 (NCT05821660) prior to the start of patient recruitment. The study was conducted in accordance with the 396 principles of the Declaration of Helsinki and the standards of Good Clinical Practice. The study visits 397 were carried out on an outpatient ambulatory basis between June and August 2023 at the Buchinger 398 Wilhelmi Clinic in Überlingen (Baden-Württemberg, Germany). Written informed consent was obtained 399 from all participants.

400 **Dietary intervention**

401 The MFP used was the Buchinger Wilhelmi FASTING BOX (Buchinger Wilhelmi Development und

- 402 Holding GmbH, Germany) which includes ready-made meal replacements to be consumed over a five-
- 403 day period. The ingredients are organic, plant-based products. The 24 items include vegetable soups as
- the main supplement, high-quality oils (linseed and algae oil) rich in omega 3 polyunsaturated fatty acids,chickpea puree, apple puree, honey and cashew nuts. The MFP provides on average 623 kcal per day,
- 405 consisting of 9.8 grams (6.2 % of caloric intake) of proteins, 41.5 grams (26.6 %) of carbohydrates, and
- 407 44.7 grams (64.7 %) of fat (Table S1). The aim of the MFP regimen is to achieve a steady reduction in
- 408 calorie intake while limiting carbohydrate consumption to less than 50 g and proteins to less than ~10 g
- 409 per day. The MFP includes a food supplement containing Tricalcium citrate, potassium citrate,
- 410 magnesium citrate, zinc citrate trihydrate, sodium chloride. Furthermore, herbal teas, soup essences and
- 411 herbal extracts are included as refreshment options, along with the recommendation to drink at least 2.5 L
- 412 non-caloric, caffeine-free beverages daily. The consumption of water and herbal tea is not restricted. A
- detailed meal plan describes the recommended daily food intake and reflects the energy, fat, carbohydrate
- 414 and protein content (Table S1).
- 415 The 5-day program begins with a transition day. This is the only day when a morning serving is provided.
- 416 On the following four MFP days, subjects skip the morning meal inducing a time-restricted eating pattern.
- 417 The entire MFP programme is gluten-free and contains only a very restricted diversity of food items. The
- 418 MFP was followed by four days of gradual food reintroduction from 800 to 1600 kcal per day. Half of the 419 intervention group received a standard food reintroduction (n=16) and half received a ketogenic food
- 419 intervention group received a standard food reintroduction (n=16) and half received a ketogenic food 420 reintroduction (n=16) (Table S2). The food was freshly cooked, organic, plant-based meals to take home
- reintroduction (n=16) (Table S2). The food was freshly cooked, organic, plant-based meals to take home
 after their daily measurements. Subjects in the control group were advised to stick to their usual diet.
- 421 after their daily measurements. Subjects in the control group were advised to stick to their usual die

422 Participants

- 423 Participants were recruited from the local area of Überlingen, Germany. Information about the study was
- 424 offered in social media and per mail. An online questionnaire was used to recruit volunteers. If they
- 425 appeared eligible, potential candidates were invited to an online presentation of the study. They were then
- invited to an assessment with the study physician, who checked the inclusion and exclusion criteria and
- 427 asked for written informed consent. Women and men between 18 and 80 years were eligible. The
- following criteria led to exclusion: (1) intake of antibiotics up to 2 months prior the study; (2) medicated
- high blood pressure; (3) diagnosed hyperuricemia; (4) diagnosed diabetes mellitus type I and II; (5)
- 430 diagnosed kidney stone; (6) active malignant diseases; (7) known substance addiction; (8) pregnancy or
- 431 breastfeeding; (9) diagnosed with cachexia, anorexia, nervosa, advanced kidney, liver or cerebrovascular

- 432 insufficiency; (10) inability to sign the informed consent and (11) participation in another study. The
- 433 participants received no fee for their study participation.

434 Measurements

- 435 After a thorough physical examination by the study physician participants were randomised to either the
- 436 intervention or control group. In order to facilitate the conduction of the study by the clinical centre, the
- 437 study was conducted in two phases, each comprising 32 participants from both the control and
- 438 intervention groups, with a one-month interval between them. For eleven consecutive days, the
- 439 participants were examined daily in the morning. Four main visits were conducted: T0 at baseline (BL)
- before the start of the intervention, T1 in the morning of the 7th day after the five-day MFP (end MFP),
- T2 in the morning of the 11th day after the subsequent four-days of food reintroduction (FR) and T3 at
- 442 follow-up one month later.

443 Endpoints

- 444 The changes in blood pressure and body weights are considered as primary endpoints. Changes in lipid
- and glucose metabolism, inflammatory parameters, total antioxidant capacity, and well-being were also
- 446 analysed using linear mixed models with adjusted p-values < 0.05 being considered significant. All other
- 447 parameters are considered as exploratory endpoints.

448 Clinical examination

- 449 Clinical parameters were measured daily by trained research assistants. Body weight was evaluated with
- 450 participants lightly dressed, utilising a Seca 704 (Seca, Hamburg, Germany). Height was measured using
- the same device. Blood pressure and heart rate were measured twice on the non-dominant arm while
- 452 seated, after a resting period, using a boso Carat professional (Bosch und Sohn GmbH u. Co. KG,
- 453 Jungingen, Germany). Waist circumference was determined using a tape, which was placed halfway
- 454 between the lowest rib and the iliac crest (openmindz GmbH, Heidelberg, Germany). Acetoacetic acid
- 455 was self-measured twice per day in the first morning and last evening urine using Ketostix (Bayer,
- 456 Leverkusen, Germany).

457 Blood parameters

- 458 Blood samples were collected at all four main visits (baseline, end of fasting, end of food reintroduction
- 459 period, follow-up) by trained medical assistants after participants had fasted overnight (Figure 1B). Lipid,
- 460 glucose, kidney, liver and inflammatory parameters were determined as described in a previous study 41 .
- 461 The antioxidative capacity of water-soluble substances (ACU) and lipid-soluble substances (ACL) was
- determined by photochemiluminiscence in serum and lipidperoxide by photometry in EDTA
- 463 plasma.TNF-alpha was measured in serum by chemiluminiscence immunoassay.

464 Questionnaires

- 465 Self-reported data was documented by completing online questionnaires in the Buchinger Wilhelmi
- 466 Amplius app. The participants received instructions and further information via this app to enable them to467 participate in this programme remotely. Adverse events were recorded in a report form by study
- 468 physicians.
- 469 Participants reported the following outcomes on all four main visits (T0-T3): The Well-being Index
- 470 World Health Organization 5 (WHO-5)⁴², International Physical Activity Questionnaire (IPAQ) short
- 471 form, Pittsburgh Sleep Quality Index (PSQI)⁴³, Short healthy eating index (sHEI)⁴⁴, and Questionnaire of
- 472 highly processed food consumption (sQ-HPF)⁴⁵. Furthermore, lifestyle habits such as smoking, and

- 473 alcohol consumption were documented. Stress level was rated on a visual scale from 0 (none) to 10
- 474 (extreme), and energy level from 0 (weak) to 10 (full of energy). Alcohol consumption was recorded as
- 475 glasses of beer (0.5 l; 2 units of alcohol), wine (0.25 l; 2 units of alcohol) or spirits (0.02 l; 1 unit of
- alcohol) per week and added up to the number of drinks per week.
- 477 Additionally, participants self-reported daily their emotional and physical well-being as well as energy
- 478 level on visual scales from 0 (very bad) to 10 (excellent). Sleep disturbances (0, none to 10, very strong)
- and sleep quality (0, calm to 10, restless) were reported. Further, participants rated whether they had
- 480 cravings, felt bloated or cold (0; strongly disagree to 10; strongly agree). Symptoms such as fatigue,
- 481 muscle weakness, back pain, headache, hunger, anxiety and digestive disorders on visual scales from 0
- 482 (none) to 10 (maximum) were evaluated. Self-perceived physical activity was recorded on a visual scale
- from 0 (inactive) to 10 (very active) and the actual activity time was captured in hours per day.

484 Faecal microbiota shotgun metagenomics

- 485 Three faecal samples were collected using EasySampler Stool Collection Kit (GP Medical Devices,
- 486 Holstebro, Denmark) at T0, T2 and T3. Samples were stabilised by DNA/RNA ShieldTM Reagent, Zymo
- 487 Research Europe GmbH, Freiburg, Germany and stored at -20°C. The samples were processed and
- 488 analysed by CeGaT, Tübingen, Germany.
- 489 Genomic DNA samples were profiled with shotgun metagenomic sequencing. Sequencing libraries were
- 490 prepared with the Illumina preparation kit (M) Tagmentation (Illumina, San Diego, CA) with 100 ng
- 491 genomic DNA following the manufacturer's protocol. Q30 value of sequencing was >90.25%. The final
- 492 library was sequenced on the NovaSeq 6000® (Illumina, San Diego, CA) platform.
- 493 Metagenomics shotgun sequencing data processing was performed as described in Ducarmon et al. ²².
- 494 Raw reads underwent quality filtering using bbduk (v38.93): 1) low-quality trimming (qtrim=rl, trimq=3),
- 495 2) discarding low-quality reads (maq=25), 3) adapter removal, and 4) length filtering (ml=45).
- 496 Taxonomic profiling used mOTUs (v3.1), while functional profiling filtered out human genome reads via
- 497 kraken2 (v2.1.2) against hg38, then mapped to a reduced GMGC human gut catalogue. Profiling of
- 498 carbohydrate-active enzymes was done using Cayman 21 .
- 499 Statistical analysis of metagenomic data was done in the statistical programming language R. Alpha-
- 500 diversity was assessed using in phyloseq. Differences between baseline and other timepoints were
- 501 statistically evaluated using a linear mixed model (LMM). Beta-diversity was determined using Bray-
- 502 Curtis dissimilarity. Differential abundance analysis was done using LMM in SIAMCAT (v2.5.1), with
- 503 participant-specific random effects . Features with <10% prevalence were excluded. Pseudocounts varied
- and were 1e-4 for taxonomic analysis or 0.01 RPKM for CAZy. FDR correction was applied to p-values,
- 505 with significance defined as adjusted p < 0.05.
- 506 Functional analyses in gut metagenome were done as described in Ducarmon et al. ²². Gene-set
- 507 enrichment analysis (GSEA) using fgsea identified higher-level CAZy substrates.

508 Serum metabolomics

- 509 Serum metabolomics was performed by lifespin GmbH (Regensburg, Germany). Sample preparation was
- 510 done from 350 μ l of serum mixed with 350 μ l of aqueous buffer. The buffer consists of H₂O p.A., 0.1 g/l
- 511 NaN₃, 0.067 mol/l Na₂HPO₄, 0.033 mol/l NaH₂PO₄ (pH: 7.15 \pm 0.05), 5% D₂O field-lock substance and
- an internal standard (6 mM pyrazine) for quantification. From this mixture, $600 \ \mu$ l were transferred into a
- 513 5 mm Bruker NMR tube and sealed with barcode-labelled lids. The final NMR samples were stored after
- 514 preparation at refrigerator temperature until measurement, not more than 24 h. NMR measurement was

performed on a Bruker AVANCE NEO 600 MHz (measuring method 1D 1H noesygppr1d_d20, NS=16, T=310K).

517

518 The spectra obtained were Fourier transformed using TopSpin software (version 4.0, Bruker Biospin,

519 Germany). All spectra were automatically phased and subjected to baseline correction. Subsequently, the

- 520 spectra were analyzed using the proprietary lifespin Profiler software (version 1.4_Blood) and a
- 521 quantitative metabolite list was generated.
- 522

523 Statistical analysis

Based on previously collected data for changes in systolic blood pressure ⁴⁶, we calculated that a sample
 size of 32 participants per arm is required to detect a decrease in 1 mm/hg per day with three groups and

526 an effect size of 0.33 with 90% power and an alpha error probability of 0.05 with an ANOVA test

- 527 including repeated measurements (G*Power version 3.1.9.7). Randomisation was performed with R, with
- a custom script splitting individuals into two groups randomly with equal mean age and weight.

529 Statistical significance for the primary endpoints was assessed using LMM. Extraction of 32 closest

neighbors of our participants, from subjects of our study with a cohort of 1422, was done using the

531 NearestNeighbors class from the module neighbors of sklearn (1.3.2). The distance computed was the

532 Euclidean, based on the following normalized parameters: BMI (kg/m^2), age, SBP, waist circumference,

triglycerides (Table S3). All statistics and tables were generated with python using the packages

534 statsmodels (0.14.0) and scipy.stats (1.11.3). Differences were calculated using unrounded values to

- maintain accuracy, with rounded values presented for clarity. For the baseline comparison we used a t-test
 with adjustment for equality of the variance depending on the outcome of a Levene test. All other
- with adjustment for equality of the variance depending on the outcome of a Levene test. All other
 comparisons were measured using mixed models with the participant ID considered as a random effect. P-
- 538 values less than 0.05 were considered to be statistically significant.
- 539
- 540
- 010

541 References

- Wilhelmi de Toledo, F., Grundler, F., Sirtori, C. R. & Ruscica, M. Unravelling the health effects
 of fasting: a long road from obesity treatment to healthy life span increase and improved
 cognition. *Ann. Med.* 52, 147-161, doi:10.1080/07853890.2020.1770849 (2020).
- 546 2 Mihaylova, M. M. *et al.* When a calorie is not just a calorie: Diet quality and timing as mediators of metabolism and healthy aging. *Cell Metab* 35, 1114-1131, doi:10.1016/j.cmet.2023.06.008
 548 (2023).
- 5493Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis550for the Global Burden of Disease Study 2019. Lancet **396**, 1223-1249, doi:10.1016/s0140-5516736(20)30752-2 (2020).
- 5524de Cabo, R. & Mattson, M. P. Effects of Intermittent Fasting on Health, Aging, and Disease. N.553Engl. J. Med. 381, 2541-2551, doi:10.1056/NEJMra1905136 (2019).
- 554
 5
 Koppold, D. A. *et al.* International consensus on fasting terminology. *Cell Metab* 36, 1779-1794.e1774, doi:10.1016/j.cmet.2024.06.013 (2024).
- 5566Sun, M. L. *et al.* Intermittent fasting and health outcomes: an umbrella review of systematic557reviews and meta-analyses of randomised controlled trials. *EClinicalMedicine* **70**, 102519,558doi:10.1016/j.eclinm.2024.102519 (2024).

 (2015). (2015). Wilhelmi de Toledo, F., Grundler, F., Bergouignan, A., Drinda, S. & Michalsen, A. Safety, health improvement and well-being during a 4 to 21-day fasting period in an observational study including 1422 subjects. <i>PLoS One</i> 14, e0209353, doi:10.1371/journal.pone.0209353 (2019). Grundler, F., Mesnage, R., Michalsen, A. & Wilhelmi de Toledo, F. Blood pressure changes in 1610 subjects with and without antihypertensive medication during long Term fasting. <i>Journal of the American Heart Association</i> 9, e018649 (2020). Baker, P. <i>et al.</i> Ultra-processed foods and the nutrition transition: Global, regional and national trends, food systems transformations and political economy drivers. <i>Obes Rev</i> 21, e13126, doi:10.1111/bof.13126 (2020). Wilhelmi de Toledo, F., Grundler, F. & Mesnage, R. World's Longest Medically Documented Repeated Fasting History in a 92 Years (2014). Brandhorts, S. <i>et al.</i> Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. <i>Nature Communications</i> 15, 1309, doi:10.1038/s141467- 024-45260-9 (2024). Kjeldsen-Kagh, J. Rheumatoid arthrifis treated with vegetarian diets. <i>The American journal of clinical nutrition</i> 70, 5948-6008 (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging</i> 1, 47-59 (2021). Congo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging</i> 1, 47-59 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and fts Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M	559 560	7	Gill, S. & Panda, S. A Smartphone App Reveals Erratic Diurnal Eating Patterns in Humans that Can Be Modulated for Health Benefits. <i>Cell Metab</i> 22 , 789-798, doi:10.1016/j.cmet.2015.09.005
 Grundler, F., Mesnage, R., Michalsen, A. & Wilhelmi de Toledo, F. Blood pressure changes in 1610 subjects with and without antihypertensive medication during long □ term fasting. <i>Journal of</i> <i>the American Heart Association</i> 9, e018649 (2020). Baker, P. <i>et al.</i> Ultra-processed foods and the nutrition transition: Global, regional and national trends, food systems transformations and political economy drivers. <i>Obes Rev</i> 21, e13126, doi:10.1111/obr.13126 (2020). Wilhelmi de Toledo, F., Grundler, F. & Mesnage, R. World's Longest Medically Documented Repeated Fasting History in a 92 Years Old Man Who Fasted 21 Days Yearly for 45 Years: A Case Report. <i>J Integr Complement Med</i> 30, 487-491, doi:10.1089/jicm.2023.0352 (2024). Brandhorst, S. <i>et al.</i> Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. <i>Nature Communications</i> 15, 1309, doi:10.1038/s41467- 024-45260-9 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. <i>The American journal of clinical nutrition</i> 70, 594-s600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging</i> 1, 47-59 (doi:10.1038/s43587-020-0001-33 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020).	562 563	8	Wilhelmi de Toledo, F., Grundler, F., Bergouignan, A., Drinda, S. & Michalsen, A. Safety, health improvement and well-being during a 4 to 21-day fasting period in an observational study
 Baker, P. <i>et al.</i> Ultra-processed foods and the nutrition transition: Global, regional and national trends, food systems transformations and political economy drivers. <i>Obes Rev</i> 21, e13126, doi:10.1111/obr.13126 (2020). Wilhelmi de Toledo, F., Grundler, F. & Mesnage, R. World's Longest Medically Documented Repeated Fasting History in a 92 Years Old Man Who Fasted 21 Days Yearly for 45 Years: A Case Report. <i>J Integr Complement Med</i> 30, 487-491, doi:10.1089/jicm.2023.0352 (2024). Brandhorst, S. <i>et al.</i> Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. <i>Nature Communications</i> 15, 1309, doi:10.1038/s41467-024-4526.09 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. <i>The American journal of clinical nutrition</i> 70, 594s-6005 (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging.</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging.</i> 1, 47-59 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2021.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long-Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). ">https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nat</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Ducarmo	565	9	Grundler, F., Mesnage, R., Michalsen, A. & Wilhelmi de Toledo, F. Blood pressure changes in
 trends, food systems transformations and political economy drivers. <i>Obes Rev</i> 21, e13126, doi:10.1111/obr.13126 (2020). Wilhelmi de Toledo, F., Grundler, F. & Mesnage, R. World's Longest Medically Documented Repeated Fasting History in a 92 Years Old Man Who Fasted 21 Days Yearly for 45 Years: A Case Report. <i>J Integr Complement Med</i> 30, 487-491, doi:10.1089/jicm.2023.0352 (2024). Brandhorst, S. <i>et al.</i> Tasting-minicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. <i>Nature Communications</i> 15, 1309, doi:10.1038/s41467-024-45260-9 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. <i>The American journal of clinical nutrition</i> 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging</i> 1, 47-59, doi:10.1038/s43587-020-00013-3 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayoep.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long-Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Lorg-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.95.90209 (2024). Ducarmon, Q. R. <i>et al.</i> Lar			
 doi:10.1111/obr.13126 (2020). Wilhelmi de Toledo, F., Grundler, F. & Mesnage, R. World's Longest Medically Documented Repeated Fasting History in a 92 Years Old Man Who Fasted 21 Days Yearly for 45 Years: A Case Report. J Integr Complement Med 30, 487-491, doi:10.1089/jicm.2023.0352 (2024). Brandhorst, S. <i>et al.</i> Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nature Communications 15, 1309, doi:10.1038/s41467- 024-45260-9 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. The American journal of clinical nutritino 70, 594s-6008 (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat. Aging, 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat Aging, 1, 47-59 (2021). Damgo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat Aging, 1, 47-59 (2022.01.012 (2022). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clin. Proc. 97, 761-776, doi:10.1016/j.mayocp.202.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. Nutrients 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. Food Chem. Toxicol. 145 (2020). <ht 10.1016="" doi.org="" j.frct.2020.111701="" styp:="">. </ht> Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Natr 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. J Am		10	1
 Wilhelmi de Toledo, F., Grundler, F. & Mesnage, R. World's Longest Medically Documented Repeated Fasting History in a 92 Years Old Man Who Fasted 21 Days Yearly for 45 Years: A Case Report. J Integr Complement Med 30, 487-491, doi:10.1089/jjcm.2023.0352 (2024). Brandhorst, S. et al. Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nature Communications 15, 1309, doi:10.1038/s41467- 024-45260-9 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. The American journal of clinical nutrition 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat. Aging. 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat Aging, 1, 47-59 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clin. Proc. 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. Nutrients 16 (2024). Grundler, F. et al. Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. Food Chem. Toxicol. 145 (2020). ">https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. et al. Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. J Am Heart Assoc 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. et al. Large-scale computational			
 Repeated Fasting History in a 92 Years Old Man Who Fasted 21 Days Yearly for 45 Years: A Case Report. J Integr Complement Med 30, 487-491, doi:10.1089/jcm.2023.0352 (2024). Brandhorst, S. et al. Fasting-minicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nature Communications 15, 1309, doi:10.1038/s41467- 024-45260-9 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. The American journal of clinical nutrition 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat. Aging. 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat. Aging 1, 47-59, doi:10.1038/s43587-020-00013-3 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clin. Proc. 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. Nutrients 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. Food Chem. Toxicol. 145 (2020). ">https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. J Am Heart Assoc 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. bioRxiv, 2024.2001.2008.574624, doi			
 Case Report. J Integr Complement Med 30, 487-491, doi:10.1089/jicm.2023.0352 (2024). Brandhorst, S. et al. Fasting-minicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nature Communications 15, 1309, doi:10.1038/s41467-024-45260-9 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. The American journal of clinical nutrition 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat. Aging. 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat. Aging. 1, 47-59, doi:10.1038/s43587-020-00013-3 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clin. Proc. 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long-Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. Nutrients 16 (2024). Grundler, F. et al. Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. Food Chem. Toxicol. 145 (2020). https://doi.org/10.1016/j.fct.2020.111701>. Herry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr & 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. et al. Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. J Am Heart Assoc 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. et al. Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. bioRxiv, 2024.2001.2008, 574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. et al. Large-scale computational ana	571	11	
 Brandhorst, S. <i>et al.</i> Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. <i>Nature Communications</i> 15, 1309, doi:10.1038/s41467- 024-45260-9 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. <i>The American journal of clinical nutrition</i> 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging</i> 1, 47-59, doi:10.1038/s43587-020-00013-3 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chitesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.04.19.590209 (2024). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.04.19.590209 (2024).<!--</td--><td>572</td><td></td><td>Repeated Fasting History in a 92 Years Old Man Who Fasted 21 Days Yearly for 45 Years: A</td>	572		Repeated Fasting History in a 92 Years Old Man Who Fasted 21 Days Yearly for 45 Years: A
 reduced biological age and disease risk. <i>Nature Communications</i> 15, 1309, doi:10.1038/s41467-024-45260-9 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. <i>The American journal of clinical nutrition</i> 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging</i> 1, 47-59 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long-Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable disease: a multicohort study. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.fac.2023.100828 (2023). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The </i>	573		Case Report. J Integr Complement Med 30, 487-491, doi:10.1089/jicm.2023.0352 (2024).
 024-45260-9 (2024). Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. <i>The American journal of clinical nutrition</i> 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging.</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging</i> 1, 47-59 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long-Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). https://doi.org/10.1016/j.fcl.2020.11701). Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chitesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Nyberg, S. T. <i>et al.</i> Objective fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.01.08.574624 (2024). Nyberg, S. T. <i>et al.</i> Objective and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i>	574	12	Brandhorst, S. et al. Fasting-mimicking diet causes hepatic and blood markers changes indicating
 Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. <i>The American journal of clinical nutrition</i> 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging</i> 1, 47-59 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long-Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). <<u>https://doi.org/10.1016/j.fct.2020.111701></u>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable disease: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HL. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacifi</i>	575		reduced biological age and disease risk. <i>Nature Communications</i> 15 , 1309, doi:10.1038/s41467-
 Kjeldsen-Kragh, J. Rheumatoid arthritis treated with vegetarian diets. <i>The American journal of clinical nutrition</i> 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging</i> 1, 47-59 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long-Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). <<u>https://doi.org/10.1016/j.fct.2020.111701></u>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable disease: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HL. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacifi</i>	576		024-45260-9 (2024).
 <i>clinical nutrition</i> 70, 594s-600s (1999). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging.</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat. Aging.</i> 1, 47-59 (doi:10.1038/s43587-020-00013-3 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Nyberg, S. T. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.01.9.8.574624 (2024). Nyberg, S. T. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.01.9.8.574624 (2024). Nyberg, S. T. <i>et al.</i> Long-term fasting remodels gut microbial metabolis	577	13	
 Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat. Aging. 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat Aging 1, 47-59, doi:10.1038/s43587-020-00013-3 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo <i>Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. Nutrients 16 (2024). Grundler, F. et al. Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. Food Chem. Toxicol. 145 (2020). ">https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. et al. Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. J Am Heart Assoc 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. et al. Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. bioRxiv, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. et al. Long-term fasting remodels gut microbial metabolism and host metabolism. bioRxiv, 2024.2004.2019.590209, doi:10.11101/2024.01.9590209 (2024). Nyberg, S. T. et al. Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. The Lancet Public Health 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related ca	578		
 longevity and disease. <i>Nat. Aging.</i> 1, 47-59 (2021). Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. <i>Nat Aging</i> 1, 47-59, doi:10.1038/s43587-020-00013-3 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo</i> <i>Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). ">https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.01.9.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related cardiovascular risk projection. <i>The Lancet Regional H</i>	579	14	
 Longo, V. D., Di Tano, M., Mattson, M. P. & Guidi, N. Intermittent and periodic fasting, longevity and disease. Nat Aging 1, 47-59, doi:10.1038/s43587-020-00013-3 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clin. Proc. 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. Nutrients 16 (2024). Grundler, F. et al. Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. Food Chem. Toxicol. 145 (2020). <<u>https://doi.org/10.1016/j.fct.2020.111701>.</u> Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. et al. Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. J Am Heart Assoc 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. et al. Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. bioRxiv, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. et al. Large-term fasting remodels gut microbial metabolism and host metabolism. bioRxiv, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. et al. Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. The Lancet Public Health 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD, Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related cardiovascular risk projection. The Lancet Regional Health – Western Pacific 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Br	580		
 longevity and disease. Nat Aging 1, 47-59, doi:10.1038/s43587-020-00013-3 (2021). Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clin. Proc. 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. Nutrients 16 (2024). Grundler, F. et al. Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. Food Chem. Toxicol. 145 (2020). . Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. et al. Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. J Am Heart Assoc 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. et al. Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. bioRxiv, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. et al. Long-term fasting remodels gut microbial metabolism and host metabolism. bioRxiv, 2024.2001.2009, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. et al. Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. The Lancet Public Health 3, e490-e497, doi:https://doi.org/10.1016/52468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related cardiovascular risk projection. The Lancet Regional Health – Western Pacific 37, doi:10.1016/j.lanvpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 		15	
 Palmer, B. F. & Clegg, D. J. Metabolic Flexibility and Its Impact on Health Outcomes. <i>Mayo</i> <i>Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayocp.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/j.52468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			
 <i>Clin. Proc.</i> 97, 761-776, doi:10.1016/j.mayoep.2022.01.012 (2022). Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wilhelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/j248-0267(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 		16	
 Grundler, F., Mesnage, R., Ruppert, P. M. M., Kouretas, D. & Wihelmi de Toledo, F. Long- Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). (https://doi.org/10.1016/j.fct.2020.111701). Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			
 Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety. <i>Nutrients</i> 16 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). (https://doi.org/10.1016/j.fct.2020.111701). Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 	585	17	
 (2024). Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.01.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 	586		
 588 18 Grundler, F. <i>et al.</i> Interplay between oxidative damage, the redox status, and metabolic biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). 590 https://doi.org/10.1016/j.fct.2020.111701>. 591 19 Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). 593 20 Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). 596 21 Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). 598 22 Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). 600 23 Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). 603 24 Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). 606 25 Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 	587		
 biomarkers during long-term fasting. <i>Food Chem. Toxicol.</i> 145 (2020). https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 		18	
 https://doi.org/10.1016/j.fct.2020.111701">https://doi.org/10.1016/j.fct.2020.111701>. Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			
 Henry, C. J. Basal metabolic rate studies in humans: measurement and development of new equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			
 equations. <i>Public Health Nutr</i> 8, 1133-1152, doi:10.1079/phn2005801 (2005). Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:<u>https://doi.org/10.1016/S2468-2667(18)30139-7</u> (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 		19	
 Chiesa, S. T. <i>et al.</i> Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. <i>J Am Heart Assoc</i> 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			
 Cardiovascular Risk in the Young. J Am Heart Assoc 11, e024380, doi:10.1161/jaha.121.024380 (2022). Ducarmon, Q. R. et al. Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. bioRxiv, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. et al. Long-term fasting remodels gut microbial metabolism and host metabolism. bioRxiv, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. et al. Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. The Lancet Public Health 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. The Lancet Regional Health – Western Pacific 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 		20	
 (2022). (2022). Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			
 Ducarmon, Q. R. <i>et al.</i> Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:<u>https://doi.org/10.1016/S2468-2667(18)30139-7</u> (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			e e e e e e e e e e e e e e e e e e e
 enabled by Cayman. <i>bioRxiv</i>, 2024.2001.2008.574624, doi:10.1101/2024.01.08.574624 (2024). Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:<u>https://doi.org/10.1016/S2468-2667(18)30139-7</u> (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 		21	
 Ducarmon, Q. R. <i>et al.</i> Long-term fasting remodels gut microbial metabolism and host metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:<u>https://doi.org/10.1016/S2468-2667(18)30139-7</u> (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			
 metabolism. <i>bioRxiv</i>, 2024.2004.2019.590209, doi:10.1101/2024.04.19.590209 (2024). Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:https://doi.org/10.1016/S2468-2667(18)30139-7 (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 		22	
 Nyberg, S. T. <i>et al.</i> Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:<u>https://doi.org/10.1016/S2468-2667(18)30139-7</u> (2018). Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			
 diseases: a multicohort study. <i>The Lancet Public Health</i> 3, e490-e497, doi:<u>https://doi.org/10.1016/S2468-2667(18)30139-7</u> (2018). 24 Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity- related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 		23	
 doi:<u>https://doi.org/10.1016/S2468-2667(18)30139-7</u> (2018). 24 Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). 606 25 Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			
 Wang, TD., Hung, CL. & Yeh, HI. Predicted but not destined: considerations for obesity-related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 			•
 related cardiovascular risk projection. <i>The Lancet Regional Health – Western Pacific</i> 37, doi:10.1016/j.lanwpc.2023.100828 (2023). Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency 		24	
605doi:10.1016/j.lanwpc.2023.100828 (2023).60625Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency		- ·	
606 25 Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency			
		25	
		-	

608 609	26	Emanuel, E. J., Dellgren, J. L., McCoy, M. S. & Persad, G. Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists. <i>N Engl J Med</i> 390 , 1839-1842, doi:10.1056/NEJMp2400978
610 611	27	(2024). Cramer, H. <i>et al.</i> Predictors of health behavior change after an integrative medicine inpatient
612 613	28	program. <i>Int J Behav Med</i> 21 , 775-783, doi:10.1007/s12529-013-9354-6 (2014). Mishra, A. <i>et al.</i> Fasting-mimicking diet prevents high-fat diet effect on cardiometabolic risk and
614 615	29	lifespan. <i>Nature Metabolism</i> 3 , 1342-1356, doi:10.1038/s42255-021-00469-6 (2021). Brandhorst, S. & Longo, V. D. Protein Quantity and Source, Fasting-Mimicking Diets, and
616		Longevity. Adv. Nutr. 10, S340 - S350 (2019).
617	30	Bianchi, V. E. Weight loss is a critical factor to reduce inflammation. <i>Clin Nutr ESPEN</i> 28, 21-
618		35, doi:10.1016/j.clnesp.2018.08.007 (2018).
619	31	Fontana, L., Partridge, L. & Longo, V. D. Extending healthy life span—from yeast to humans.
620		<i>Science</i> 328 , 321-326 (2010).
621	32	Longo, Valter D. & Mattson, Mark P. Fasting: Molecular Mechanisms and Clinical Applications.
622		Cell Metab 19, 181-192, doi: <u>https://doi.org/10.1016/j.cmet.2013.12.008</u> (2014).
623	33	Wei, M. et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and
624		cardiovascular disease. Sci. Transl. Med. 9, eaai8700 (2017).
625	34	van den Burg, E. L. et al. Integration of a fasting-mimicking diet programme in primary care for
626		type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month
627		randomised controlled trial. Diabetologia 67, 1245-1259, doi:10.1007/s00125-024-06137-0
628		(2024).
629	35	Videja, M. et al. Fasting-Mimicking Diet Reduces Trimethylamine N-Oxide Levels and Improves
630		Serum Biochemical Parameters in Healthy Volunteers. Nutrients 14, 1093 (2022).
631	36	Brandhorst, S. et al. Fasting-mimicking diet causes hepatic and blood markers changes indicating
632		reduced biological age and disease risk. Nature Communications 15, 1309 (2024).
633	37	Sülz, S., van Elten, H. J., Askari, M., Weggelaar-Jansen, A. M. & Huijsman, R. eHealth
634		Applications to Support Independent Living of Older Persons: Scoping Review of Costs and
635		Benefits Identified in Economic Evaluations. J Med Internet Res 23, e24363, doi:10.2196/24363
636		(2021).
637	38	Sagastume, D. et al. The effectiveness of lifestyle interventions on type 2 diabetes and gestational
638		diabetes incidence and cardiometabolic outcomes: A systematic review and meta-analysis of
639		evidence from low- and middle-income countries. EClinicalMedicine 53, 101650,
640		doi:10.1016/j.eclinm.2022.101650 (2022).
641	39	Hollander, J. E. & Carr, B. G. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med 382,
642		1679-1681, doi:10.1056/NEJMp2003539 (2020).
643	40	Omboni, S. et al. Evidence and Recommendations on the Use of Telemedicine for the
644		Management of Arterial Hypertension. Hypertension 76, 1368-1383,
645		doi:10.1161/HYPERTENSIONAHA.120.15873 (2020).
646	41	Wilhelmi de Toledo, F., Grundler, F., Bergouignan, A., Drinda, S. & Michalsen, A. Safety, health
647		improvement and well-being during a 4 to 21-day fasting period in an observational study
648		including 1422 subjects. <i>PLoS One</i> 14 (2019). < <u>https://doi.org/10.1371/journal.pone.0209353</u> >.
649	42	Topp, C. W., Østergaard, S. D., Søndergaard, S. & Bech, P. The WHO-5 Well-Being Index: A
650		Systematic Review of the Literature. Psychotherapy and Psychosomatics 84, 167-176,
651		doi:10.1159/000376585 (2015).
652	43	Buysse, D. J., Reynolds III, C. F., Monk, T. H., Berman, S. R. & Kupfer, D. J. The Pittsburgh
653		Sleep Quality Index: a new instrument for psychiatric practice and research. <i>Psychiatry Res.</i> 28,
654		193-213 (1989).
655	44	Lavelle, G. et al. Validity of the international physical activity questionnaire short form (IPAQ-
656		SF) as a measure of physical activity (PA) in young people with cerebral palsy: A cross-sectional
657		study. <i>Physiotherapy</i> 107 , 209-215 (2020).

Martinez-Perez, C. *et al.* Integrative development of a short screening questionnaire of highly
 processed food consumption (sQ-HPF). *International Journal of Behavioral Nutrition and Physical Activity* 19, 6 (2022).

- 661 46 Grundler, F., Mesnage, R., Michalsen, A. & Wilhelmi de Toledo, F. Blood pressure changes in
 662 1610 subjects with and without antihypertensive medication during long-term fasting. *J Am Heart*663 Assoc 9 (2020). <<u>https://doi.org/10.1161/JAHA.120.018649</u>>.
- 664
- 665

666 ADDITIONAL INFORMATION

667

670

668 ACKNOWLEDGMENTS

669 We are grateful for the continuous support of the whole staff of Buchinger Wilhelmi Clinics.

671 FUNDING

672 The study was financed by Buchinger Wilhelmi Development & Holding GmbH. Further funding was

673 provided by the LUMC (LUMC Fellowship to G.Z.), the Health + Life Science Alliance Heidelberg

674 Mannheim through state funds approved by the State Parliament of Baden-Württemberg (postdoctoral

fellowships to Q.D.) and EMBO postdoctoral fellowship (ALTF 1030-2022 to Q.D.).

676

677 COMPETING INTERESTS

Authors FG, RM, AH and FWT are employees of the Buchinger Wilhelmi Development and Holding
GmbH. Authors SS, SH, RG are employees of lifespin GmbH. The remaining authors declare no
competing.

681

682 CODE AVAILABILITY

- 683 The code used to perform the statistical analysis is available upon request. Scripts used to process the684 shotgun metagenomics data are available on GitHub.
- 685

686 AUTHOR CONTRIBUTIONS

FG, FWT, and RM conceptualized and designed the study. AH contributed to statistical analyses, with
support from RM. SS, SH and RH performed the metabolomics analysis. QRD and GZ performed the
shotgun metagenomics analysis. BMT and MRM contributed to data analyses and interpretations. RM,
FG and FWT drafted the initial version manuscript. RM wrote the final version of the manuscript. All
authors reviewed, edited, and approved the final version of the manuscript.

692

693 DATA AVAILABILITY

Raw metagenomic data will be made available upon acceptance of the manuscript under accession

number PRJEB75353 at ENA.

696

697

699 SUPPLEMENTARY MATERIAL



Retoring the moning of the product o

Figure S1. Ketonuria in the group of 32 participants in the MFP arm. Ketosis was not detectable in
 the control group. Data as mean ± SD.

	Day 1	Day 2 -4	Day 5
	Transition	Fast Reset Day	Restart
Breakfast	Yoghurt 1.5 % fat	-	-
	Cashews		
	Oil		
Lunch	Soup,	Soup	Apple puree
	Oil	Chickpea puree	Cashews
		Oil	Oil
Dinner	Soup	Soup	Soup
	Oil	Chickpea puree	Oil
		Oil	
During the day	Mineral capsule	Mineral capsule	Mineral capsule
	Herbal tea	Herbal tea	Herbal tea
	Herbal extract	Herbal extract	Herbal extract
		Soup essence	Soup essence
Energy (kcal)	648.4	600	620.7
Fat (g)	44.6 (61.9 %)	47.0 (70.5 %)	42.5 (61.6 %)
Carbohydrate (g)	43.8 (27.0 %)	32.8 (21.9 %)	47.9 (30.9 %)
Protein (g)	16.1 (9.9 %)	7.0 (4.7 %)	6.2 (4.0 %)

711 Table S1. Meal plan during the 5-day MFP and the energy and macronutrient content provided.

712

713

714 Table S2. Food reintroduction for the ketogenic group and the non-ketogenic group

715

716 Standard non-ketogenic food reintroduction

Day of breaking	Lunch:	150g applesauce homemade
the fast	2:00 p.m.	1 raw apple or applesauce homemade
	Supper:	380ml creamy potato soup
1st food-	Breakfast:	2 prunes
reintroduction day		Spelt porridge with fig puree and apple, orange juice
800 kcal		Herbal tea or malt coffee
	Lunch:	Leaf salads with vinaigrette
		Quark-oil-cream
		Mashed potatoes with freshly steamed spinach
	Snack:	150g yoghourt (1.5% fat), 4 nuts
	Supper:	Fennel salad
		Vegetable plate with a rice ball in saffron sauce
2nd food-	Breakfast:	2 prunes
reintroduction day		Muesli (quark, linseed oil, fruits, oats)
1000 kcal		Herbal tea or grain coffee
	Lunch:	Leaf salads with vinaigrette

		Quark-oil-cream Quinoa souffle with vegetable cubes, tomato with aubergine caviar on zucchini foam with parmesan cheese
	Snack:	150g yoghourt (1.5% fat), 4 nuts
	Supper:	Zucchini salad and jacket potatoes with quark-oil-cream
	Supper.	and beetroot
		Herbal tea or malt coffee
3rd food-	Breakfast:	1 apple
reintroduction day		Muesli (quark, linseed oil, fruits, oats)
1200 kcal		Herbal tea or grain coffee
	Lunch:	Leaf salads with sauerkraut
		Quark-oil-cream
		Chicory au gratin with quinoa
	Snack:	150g yoghourt (1.5% fat), 4 nuts
	Supper:	1 kiwi
		Celery salad
		Millet soufflé (normal soufflé with vegetable cubes with
		vegetable sauce and vegetables of the day)
		Herbal tea or grain coffee
4th food-	Breakfast:	Muesli (quark, linseed oil, fruits, oats)
reintroduction day		Quark-oil-cream and crispbread
1600 kcal		Herbal tea and grain coffee
	Lunch:	Quark-oil-cream
		light dish of the day
	Snack:	20g nuts
	Supper:	Raw carrot vegetables with apple
		light dish of the day
		Herbal tea and grain coffee

718

719 Ketogenic food reintroduction

Day of breaking	Lunch:	200g zucchini puree
the fast	2:00 p.m.	5 almonds
	Supper:	200g vegetables (e.g., 100g fennel + 100g carrots)
		1 tbsp olive oil
1st food-	Breakfast:	100g dairy product mixed with 1 tbsp flaxseed oil
reintroduction day		50g fruit
800 kcal		1 tbsp coconut flakes, 1 tbsp chia seeds
		Herbal tea or grain coffee
	Lunch:	Chicory salad with avocado vinaigrette
		Quark-oil-cream
		100g spinach and 100g broccoli
		1 tbsp olive oil
	Snack:	5 Almonds
	Supper:	200ml vegetable soup (without potatoes)
		200g vegetable plate (e.g., celery, tomato, kohlrabi)
		1 tbsp vegan pesto, 1 tbsp olive oil
		Herbal tea or grain coffee

2nd food-	Breakfast:	150g dairy product mixed with 1 tbsp flaxseed oil
reintroduction day		50g fruit
1000 kcal		1 tbsp chopped almonds, 1 tbsp chia seeds
		Herbal tea or grain coffee
	Lunch:	Summer salad with green leaves, 100g tomato, 60g avocado, 2
		tbsp sprouts, and 60ml avocado vinaigrette
		Quark-oil-cream
	Snack:	20g walnuts
	Supper:	Green salad with 1 grated fennel or kohlrabi, 1 tbsp pumpkin
	2 upp on	seeds, vinaigrette
		Omelette made from 1 egg, served with 200g broccoli and 1
		tbsp sunflower seeds
		1 tbsp olive oil
		Herbal tea or grain coffee
3rd food-	Breakfast:	200g coconut yoghourt mixed with 1 tbsp flaxseed oil and 1
reintroduction day	Dicultust.	tbsp lemon juice
1200 kcal		50g fruit
1200 Kedi		2 tbsp coconut flakes, 1 tbsp chia seeds
		Herbal tea or grain coffee
	Lunch:	Summer salad with green leaves, ¹ / ₂ pepper, 100g grated
	Lunch.	zucchini or radishes, 60ml avocado vinaigrette, 40g feta cheese,
		and 60g avocado
		Quark-oil-cream
		50g keto bread
		1 tbsp olive oil
	Snack:	20g walnuts
		Green salad with 100g grated celery salad, 1 tbsp chopped
	Supper:	almonds, and 60ml avocado vinaigrette
		100g smoked tofu with 1 tsp olive oil
		200g vegetable plate (e.g., 100g fennel, zucchini, spinach, or
		chard, with 1 tbsp pesto)
		1 tbsp olive oil
		Herbal tea or grain coffee
4th food-	Breakfast:	200g dairy product mixed with 2 tbsp flaxseed oil and 1 tbsp
reintroduction day	Dieakiast.	
1600 kcal		lemon juice 50g fruit
1000 Kcai		
		1 tbsp chopped almonds, 1 tbsp sunflower seeds, 1 tbsp chia seeds
	Lunch:	Herbal tea and grain coffee Gazpacho (100g tomato, 200g cucumber, 100g bell pepper, 2
	Lunch.	
		tbsp olive oil, and garnished with 1 tbsp chopped herbs, scallions, or cress)
		Sautéed spinach with some onions in 1 tsp olive oil
		Omelette (2 eggs with 1 tbsp Parmesan), served with 100g
		tomato sauce
	Speeler	1 tbsp olive oil
	Snack:	20g walnuts
	Supper:	Mixed salad (green leaves, arugula, tomato, cucumber,
		zucchini, bell pepper, and herbs)
		2 tbsp green olives

3 tbsp olive oil and 2 tbsp lemon juice or vinegar dressing 100g goat cheese or 200g cottage cheese mixed with 1 tbsp
olive oil and herbs
Herbal tea and grain coffee

721

- 722
- 723

724 Table S3. Baseline data comparison between the 32 closest neighbours of our participants extracted

- 725 from subjects of our study with a cohort of 1422 participants. The distance computed was the
- Euclidean, based on the following normalised parameters: BMI (kg/m²), age, SBP, waist circumference,
- 727 triglycerides. P-value is from a t-test.

	MFP	Closest neighbours PF (n	p-value
	(n =32)	=32)	
Women (n, %)	22 (68.8)	22	1
Men (n, %)	10 (31.2)	10	1
Age (years)	41.5 ± 12.88	44.91 ± 12.76	0.292
BMI	25.35 ± 2.67	25.27 ± 2.61	0.897
Waist circumference	82.85 ± 9.44	84.69 ± 10.69	0.460
SBP	132.1 ± 15.4	127.84 ± 12.76	0.237
Triglycerides	88.44 ± 49.64	99.77 ± 44.76	0.341

728

729

730 Table S4. Study demographic data.

	MFP	Control	p-value
Women (n, %)	22 (68.8)	20 (62.5)	0.79
Men (n, %)	10 (31.2)	12 (37.5)	
Age (years)	41.5 ± 12.88	44.625 ± 14.03	0.3569
Ethnicity (n, %)			
§ Caucasian	30 (93.8)	32 (100.0)	
§ Afro-American	1 (3.1)		
§ Hispano-American	1 (3.1)		
Smoking (n, %)			
§ Never	18 (56.3)	19 (59.4)	
§ Former	13 (40.6)	13 (40.6)	
§ Current	1 (3.1)	-	
Alcohol consumption	2.05 ± 4.38	2.43 ± 4.5	0.559
(units/week)			

731

733 Table S5. Differences in clinical parameters between the ketogenic food reintroduction and the

734 standard food reintroduction. The p-value indicates the statistical significance in a linear-mixed model 735 where the effects of the effects between the ketogenic food reintroduction and the non-ketogenic food

reintroduction for the participants receiving the MFP at the same timepoint (*, p < 0.05; **, p < 0.01;

736

737 ***, *p* < 0.001). # *Primary endpoints*.

	Ketogen	ic food rein sto		[mean ±	Non Ketogenic food reintroduction [mean ± std]					P-v	alues	
	T0	T1	T2	T3	T0	T1	T2	T3	T0	T1	T2	T3
P-LCR (%)	31.67 ± 5.33	33.94 ± 6.58	32.89 ± 6.0	32.12 ± 6.16	29.03 ± 3.28	30.04 ± 4.09	33.92 ± 3.68	31.02 ± 5.03	0.15 7	0.97 7	<0.00 1	0.05 3
Urea (mmol/l)	4.65 ± 0.98	3.37 ± 1.13	4.15 ± 1.22	5.22 ± 1.6	5.38 ± 1.47	3.72 ± 0.89	3.34 ± 0.77	5.23 ± 1.36	0.10 5	0.35 6	<0.00 1	0.07 5
PTT (sec)	31.39 ± 3.03	33.0 ± 3.24	33.89 ± 3.8	31.33 ± 3.11	31.5 ± 2.85	32.64 ± 4.2	32.21 ± 3.42	30.93 ± 2.73	0.91 7	0.42 9	0.003	0.38 4
PDW (fl)	12.88 ±1.36	13.35 ± 1.77	13.13 ± 1.46	12.94 ± 1.68	12.27 ± 1.01	12.64 ± 1.12	13.45 ± 1.04	12.75 ± 1.48	0.22 3	0.58 4	0.008	0.10 5
MPV (fl)	10.94 ± 0.77	11.12 ± 0.78	$\begin{array}{c} 10.93 \\ \pm \ 0.8 \end{array}$	$\begin{array}{c} 10.88 \\ \pm 0.7 \end{array}$	$\begin{array}{c} 10.55 \\ \pm \ 0.52 \end{array}$	$\begin{array}{c} 10.55 \\ \pm 0.52 \end{array}$	11.09 ± 0.54	10.75 ± 0.75	0.15 6	0.79 6	0.009	0.16 3
Plasma Lipid Peroxides (µmol/l)	385.61 ± 189.65	344.72 ± 200.34	382.06 ± 239.17	406.28 ± 242.82	388.36 ± 214.6	295.5 ± 238.2	274.07 ± 204.83	321.86 ± 218.39	0.97 0	0.26 2	0.017	0.06
Gamma GT (U/l)	21.94 ± 13.44	18.72 ± 10.93	15.33 ± 8.47	24.28 ± 19.27	15.21 ± 3.96	13.21 ± 2.52	12.57 ± 2.9	16.86 ± 4.7	0.08 1	0.60 1	0.089	0.76 8
Magnesium (mmol/l)	0.83 ± 0.06	0.84 ± 0.06	0.81 ± 0.07	0.81 ± 0.06	0.85 ± 0.05	0.85 ± 0.06	0.81 ± 0.07	0.84 ± 0.06	0.21 7	0.59 1	0.114	0.86 5
Serum Glucose (mmol/l)	4.71 ± 0.38	$\begin{array}{c} 4.24 \pm \\ 0.55 \end{array}$	$\begin{array}{c} 4.48 \pm \\ 0.47 \end{array}$	4.75 ± 0.49	$\begin{array}{c} 4.82 \pm \\ 0.41 \end{array}$	3.71 ± 0.53	4.3 ± 0.51	$\begin{array}{c} 4.83 \pm \\ 0.38 \end{array}$	0.43 1	0.00 1	0.126	0.85 8
Stress (0- 10)	5.22 ± 2.13	4.12 ± 2.85	4.24 ± 2.41	3.94 ± 2.22	5.86 ± 2.21	3.93 ± 2.13	3.62 ± 2.69	4.54 ± 2.3	0.45 5	0.33 7	0.137	0.85 1
GPT (U/l)	21.17 ± 6.7	$\begin{array}{c} 23.94 \pm \\ 10.0 \end{array}$	21.67 ± 6.89	21.89 ± 11.52	23.0 ± 4.21	29.21 ± 14.33	28.93 ± 15.63	19.71 ± 6.29	0.37 8	0.35	0.14	0.27 6
Creatinine (µmol/l)	66.46 ± 12.17	70.1 ± 14.24	65.97 ± 10.96	64.84 ± 8.57	72.76 ± 12.59	77.94 ± 13.48	75.28 ± 14.77	70.17 ± 13.76	0.16 3	0.46 6	0.154	0.64 7
WHO-5 (0- 100)	69.56 ± 11.57	63.06 ± 22.91	75.53 ± 10.09	78.12 ± 13.94	64.86 ± 19.42	70.29 ± 24.79	80.0 ± 15.92	78.57 \pm 20.49	0.46	0.04 2	0.19	0.36 3
Muscle (0- 10)	1.72 ± 2.27	2.47 ± 3.04	1.29 ± 1.79	0.82 ± 1.42	2.36 ± 2.34	1.43 ± 1.6	1.0 ± 1.78	1.54 ± 1.94	0.39 5	0.01 1	0.194	0.92 4
LDL-C (mmol/l)	3.16 ± 1.3	2.92 ± 1.07	2.43 ± 0.73	3.31 ± 1.27	3.22 ± 0.72	$\begin{array}{c} 3.22 \pm \\ 0.88 \end{array}$	2.74 ± 0.88	3.25 ± 0.93	0.87 3	0.24 9	0.238	0.60 1
Insulin (mIU/l)	6.28 ± 2.42	3.28 ± 2.16	3.61 ± 1.46	5.67 ± 2.33	6.79 ± 6.33	2.79 ± 1.12	5.64 ± 4.36	7.43 ± 2.47	0.75 6	0.45 3	0.253	0.34 6
Total Cholesterol (mmol/l)	5.08 ± 1.4	4.75 ± 1.16	4.25 ± 0.86	5.26 ± 1.34	4.85 ± 0.85	4.71 ± 0.92	4.22 ± 0.91	5.01 ± 0.92	0.58 3	0.29 7	0.278	0.94 3
ACU Urate- independent Antiox Cap (µmol/l)	79.11 ± 20.83	74.22 ± 23.35	83.44 ± 15.34	71.17 ± 15.75	81.5 ± 27.13	68.21 ± 14.94	76.57 ± 15.57	67.21 ± 15.84	0.78 0	0.33 4	0.286	0.46 5

MCH (pg)	29.77 ± 1.57	29.89 ± 1.69	29.9 ± 1.77	30.22 ± 1.86	29.78 ± 1.7	29.8 ± 1.64	29.73 ± 1.69	29.55 ± 1.65	0.99 1	0.58 2	0.304	0
TT ' A '1	289.8		349.28	285.17	296.55	474.14	330.11	288.48				0.00
Uric Acid (µmol/l)	±	400.83 ±116.9	±	±	±	±	±	±	0.79 6	0.01	0.325	0.89 6
(μποι/1)	72.76		96.47	50.12	72.62	140.32	74.21	58.45		1		
HbA1c (%)	$5.37 \pm$	5.33 ±	5.35 ±	$5.42 \pm$	$5.31 \pm$	$5.24 \pm$	$5.25 \pm$	$5.38 \pm$	0.48	0.36	0.331	0.70
1101110 (70)	0.22	0.24	0.24	0.26	0.26	0.27	0.28	0.28	4	0.50	0.551	3
PSQI (0-20)	8.72 ± 3.79	8.35 ± 3.48	6.94 ± 2.97	7.59 ± 2.81	8.21 ± 2.69	6.86 ± 2.18	5.54 ± 1.61	5.64 ± 2.13	0.61 7	0.3	0.345	0.13 6
Non-HDL-	3.21 ±	3.0 ±	2.64 ±	3.48 ±	3.16 ±	3.2 ±	2.75 ±	3.44 ±	0.88	0.16	0.040	0.93
C (mmol/l)	1.37	0.99	0.77	1.3	0.66	0.75	0.85	0.75	9	6	0.368	6
Leukocytes	5.98 ±	5.0 ±	4.65 ±	5.79 ±	5.39 ±	4.92 ±	4.53 ±	5.19 ±	0.46	0.33	0.374	0.99
(Tsd./µl)	2.62	1.24	1.66	1.61	1.63	1.65	1.65	1.32	5	2	0.574	4
RDW (%)	12.94	$12.56 \pm$	12.72	13.06	12.79	$12.5 \pm$	12.43	12.86	0.61	0.55	0.437	0.81
KD W (70)	± 0.87	0.92	± 0.89	± 0.87	± 0.89	0.76	± 0.76	± 0.77	7	2	0.437	9
GFR	103.06	98.89 ±	103.06	105.61	95.07	94.57	98.43	102.36	0.20	0.39		0.27
(ml/min)	±	15.18	±	±	±	±	± 19.7	±	2	8	0.439	6
()	13.26	15.10	12.51	12.83	21.23	17.69	_ 1)./	19.85		0		Ŭ
0.1105	24.46	$19.07 \pm$	18.36	21.31	27.69	29.06	$18.7 \pm$	26.36	0.31	0.25	0.465	0.64
sQ-HPF	± 7.64	5.64	± 5.84	± 7.14	±	±	5.23	±	2	8	0.465	5
					10.73	14.43		12.86	0.00	0.00		0.04
MCV (fl)	87.69	86.96 ±	86.93	89.06	87.48	86.64	86.29	87.52	0.90	0.88	0.518	0.04
	± 5.16	4.38	± 4.42	± 4.79	± 4.57	± 3.9	± 3.6	± 3.95	2	3		5
LDL/HDL	1.86 ±	$1.82 \pm$	1.67 ±	$2.01 \pm$	2.11 ±	2.34 ±	$2.01 \pm$	2.26 ±	0.46	0.08	0.556	0.97
(ratio)	1.04	0.96	0.87	1.02	0.91	1.15	0.98	1.05	7	3		1
Hemoglobi	13.68	$13.93 \pm$	13.42	13.74	14.44 ± 1.02	14.51	14.06	14.16	0.07	0.43	0.571	0.14
n (g/dl)	± 1.24	1.03	± 1.03	± 1.12		± 1.15	± 1.21	± 0.91	1	7		0.47
HbA1c	35.39	34.89 ±	35.0 ±	35.78	$34.5 \pm$	33.79	33.86	35.21	0.34	0.63	0.577	0.47
(mmol/mol)	± 2.38	2.78	2.5	± 2.94	2.9	± 3.07	± 2.98	± 3.17	8	8		5
HDL-C	1.87 ± 0.48	1.75 ± 0.51	$1.62 \pm$	1.78 ± 0.45	1.68 ± 0.55	$1.51 \pm$	$1.47 \pm$	1.57 ± 0.5	0.31	0.54 9	0.608	0.78
(mmol/l)	0.48 40.23	0.51	0.44 39.0 ±	0.45 40.51	0.55 42.42	0.47 42.19	0.37	0.5 41.97	2 0.05	9		1 0.34
Hematocrit (%)	± 3.26	40.52 ± 2.73	39.0 ± 2.51	± 3.37	± 2.67	± 2.19 ± 2.93	40.81 ± 3.23	± 2.62	0.05	0.5	0.616	0.34
(%)	± 3.20 243.28	2.75	2.31	± 3.37 237.5	± 2.07 250.29	± 2.93 216.76	± 3.23 224.86	± 2.02 265.14	1			2
Platelets	243.20 ±	240.28	±	237.3 ±	230.29 ±	±	224.80 ±	203.14 ±	0.72	0.12	0.619	0.29
(Tsd./µl)	52.02	± 54.49	58.27	74.64	60.42	72.74	56.25	76.22	7	4	0.017	9
Potassium	4.28 ±	4.06 ±	4.26 ±	4.25 ±	4.41 ±	4.36 ±	4.32 ±	4.46 ±	0.40	0.29		0.65
(mmol/l)	0.42	4.00 ± 0.2	4.20 ± 0.3	0.46	0.49	0.47	0.37	0.4	3	2	0.655	5
Joint pain	2.17 ±	1.76 ±	1.06 ±	1.59 ±	2.57 ±	0.79 ±	1.0 ±	1.62 ±	0.61	0.06		
(0-10)	2.75	2.82	1.82	2.32	2.68	1.63	1.41	2.14	9	3	0.679	0.58
Headache	2.78 ±	3.18 ±	1.06 ±	1.18 ±	2.0 ±	1.14 ±	0.69 ±	$0.62 \pm$	0.32	0.11		0.82
(0-10)	2.49	3.32	1.75	2.13	2.39	1.51	1.8	1.45	5	7	0.683	9
	102.0				102.71		95.36	99.64		0.04		
Ouick (%)	±	90.0 ±	93.5 ±	100.83	±	90.14	±	±	0.85	0.84	0.688	0.50
	11.22	7.13	6.67	± 7.97	10.56	± 6.92	10.51	10.47	6	1		3
Calcium	2.33 ±	2.34 ±	2.35 ±	2.38 ±	2.33 ±	2.39 ±	2.36 ±	2.38 ±	0.95	0.11	0.605	0.83
(mmol/l)	0.09	0.08	0.08	0.12	0.1	0.1	0.06	0.12	6	0.11	0.695	9
TNF alpha	5.56 ±	5.24 ±	5.41 ±	5.48 ±	6.21 ±	6.51 ±	5.91 ±	$5.86 \pm$	0.26	0.13	0.701	0.49
(pg/ml)	1.34	1.09	1.03	1.23	1.94	1.33	1.15	1.35	4	6	0.701	8
Erythrocyte	4.6 ±	4.67 ±	4.5 ±	$4.56 \pm$	$4.86 \pm$	4.87 ±	4.73 ±	$4.8 \pm$	0.07	0.50	0.756	0.82
s (Mio/µl)	0.43	0.4	0.39	0.46	0.32	0.31	0.32	0.29	3	5	0.756	5
Stomach	1.94 ±	0.65 ±	1.12 ±	1.12 ±	1.36 ±	1.0 ±	$0.85 \pm$	$0.85 \pm$	0.36	0.14	0.766	0.76
ache (0-10)	1.92	1.22	1.8	1.76	2.21	1.75	2.03	1.77	4	6	0.700	6
TG	1.0 ±	$0.89 \pm$	0.9 ±	1.01 ±	0.99 ±	0.93 ±	$0.84 \pm$	1.3 ±	0.94	0.77	0.795	0.05
(mmol/l)	0.55	0.22	0.26	0.64	0.6	0.19	0.33	0.87	3	7	0.195	4
IPAQ	2926.7	7007.53	2365.1	7072.0	2841.3	4791.9	2861.3	3049.2				
(MET-	9 ±	±	$2 \pm$	4 ±	$2 \pm$	4 ±	6 ±	±	0.71	0.36	0.795	0.17
min/week)	2454.4	10007.2	2031.9	9934.1	1917.5 8	4633.8 9	4528.9	3471.7 9	9	0.50	0.195	3
IIIIII/Weeki	7	8	9	1			9					

Physical activity (hours/wee k)	14.22 ± 15.76	23.61 ± 23.92	12.06 ± 14.27	12.78 ± 12.53	5.27 ± 3.59	16.46 ± 18.67	4.82 ± 2.23	7.42 ± 4.01	0.09 2	0.71	0.799	0.66 8
TSH (mE/l)	2.55 ± 1.25	1.87 ± 0.91	1.95 ± 0.81	1.98 ± 0.89	2.02 ± 0.92	1.36 ± 0.7	1.47 ± 0.74	2.13 ± 1.21	0.19 2	0.95 5	0.806	0.00 5
ESR (mm/h)	3.33 ± 2.74	2.83 ± 1.34	2.44 ± 1.15	3.89 ± 3.16	3.0 ± 3.21	4.57 ± 9.06	2.43 ± 0.94	4.21 ± 6.4	0.75 3	0.15 5	0.828	0.65 1
Backache (0-10)	3.94 ± 3.0	2.18 ± 2.4	1.76 ± 2.44	2.18 ± 2.67	3.57 ± 2.85	1.29 ± 2.16	1.38 ± 2.06	2.0 ± 1.96	0.67 5	0.58	0.873	0.91
Energy level (0-10)	6.06 ± 2.18	5.24 ± 2.46	6.71 ± 2.49	6.71 ± 1.4	7.29 ± 1.49	6.43 ± 2.5	7.92 ± 1.89	7.92 ± 1.5	0.09 3	0.92 8	0.897	0.95 2
INR	0.99 ± 0.07	1.08 ± 0.06	1.05 ± 0.05	1.0 ± 0.05	0.99 ± 0.06	1.08 ± 0.06	1.04 ± 0.08	1.01 ± 0.07	0.84 9	0.82 4	0.905	0.37 7
AP (U/l)	61.67 ± 16.31	57.22 ± 13.86	54.44 ± 12.51	63.39 ± 22.43	67.43 ± 29.27	63.93 ± 28.88	59.86 ± 23.98	62.43 ± 25.01	0.48 4	0.75 5	0.908	0.02 7
Heartburn (0-10)	1.56 ± 2.57	$\begin{array}{c} 0.82 \pm \\ 1.88 \end{array}$	0.41 ± 0.87	0.29 ± 0.59	1.29 ± 1.77	0.29 ± 0.73	0.15 ± 0.55	0.46 ± 0.97	0.61 2	0.56 4	0.912	0.62 5
Sodium (mmol/l)	140.17 ± 2.15	139.78 ± 2.21	139.44 ± 1.89	139.33 ± 2.06	139.29 ± 3.15	136.5 ± 2.21	138.64 ± 2.56	140.29 ± 2.52	0.35 4	0.00 5	0.926	0.03 2
MCHC (g/dl)	33.98 ± 0.89	34.36 ± 0.73	34.39 ± 0.98	33.93 ± 0.69	34.04 ± 1.23	34.4 ± 1.08	34.43 ± 0.81	33.75 ± 1.13	0.87 5	0.95 2	0.942	0.48 3
GOT (U/l)	16.17 ± 5.53	24.11 ± 12.63	19.0 ± 7.18	20.5 ± 11.72	17.86 ± 5.27	30.0 ± 19.17	20.5 ± 10.89	16.21 ± 3.95	0.38 9	0.31	0.963	0.14 9
ACL Lipid- soluble Antiox Cap (µmol/l)	42.06 ± 10.54	39.72 ± 9.37	37.17 ± 6.11	39.22 ± 12.92	33.5 ± 9.78	30.36 ± 7.27	28.64 ± 5.5	38.0 ± 8.08	0.02 5	0.82 2	0.993	0.04 2
CRP (mg/l)	1.56 ± 2.32	1.96 ± 2.31	1.66 ± 2.38	1.39 ± 2.48	0.81 ± 1.25	1.4 ± 2.06	0.91 ± 1.19	0.76 ± 0.73	0.29 0	0.79 4	0.994	0.86 6

739

740 **Table S6. Comparison of the effects of the MFP and the PF.** The effects of the MFP were compared to

those of 32 matched individuals doing 5 day PF with a linear mixed model (participants as random

effects). P interaction shows whether the changes between MFP and PF are different. The p baseline is thecomparison of the MFP and PF baseline values.

744

	PF - T0	PF - fasting	MFP - TO	MFP - T1	p interaction	p baseline
AP (U/l)	60.516	59.798	64.188	60.323	0.052	0.44
Acetoacetic acid (mg/dL)	1.4	40.8	0.781	21.774	0.001	0.263
BMI (kg/m ²)	25.266	24.286	25.352	24.343	0.118	0.897
CRP (mg/l)	1.39	3.383	1.231	1.745	0.026	0.753
Ca (mmol/l)	2.325	2.356	2.332	2.362	0.974	0.752
Creatinine (mg/dl)	0.809	0.845	0.783	0.836	0.367	0.467
DBP (mmHg)	80.625	76.75	84.581	81.161	0.969	0.102
EWB (0-10)	6.84	7.68	6.844	8.065	0.476	0.995

	1					
Erythrocytes (Mio/µl)	4.732	4.8	4.712	4.757	0.6	0.848
GGT (U/l)	18.56	18.155	19	15.258	0.137	0.877
GOT (U/l)	20.151	29.977	16.906	27	0.919	0.022
GPT (U/l)	22.865	26.827	21.969	26.484	0.834	0.662
HDL-C (mg/dl)	62.085	52.282	69.094	63.645	0.088	0.122
Haemoglobin (g/dl)	14.197	14.397	14.012	14.248	0.877	0.532
HbA1c (mmol/mol)	32.616	31.421	35	34.323	0.067	0.007
INR	0.983	1.047	0.991	1.081	0.039	0.630
K (mmol/l)	4.303	4.481	4.338	4.197	0.002	0.71
LDL-C (mg/dl)	136.444	133.082	123.375	119.161	0.639	0.178
LDL/HDL ratio	2.325	2.706	1.969	2.071	0.024	0.127
Leucocytes (103/µl)	5.844	5.819	5.719	4.884	0.117	0.778
MCH (pg)	30	30	29.775	29.997	0.314	0.519
MCHC (g/dl)	34	34.594	34.009	34.432	0.435	0.972
MCV (fl)	88.594	87.031	87.6	87.123	0.052	0.355
Mg (mmol/l)	0.873	0.883	0.839	0.845	0.716	0.024
Na (mmol/l)	139.75	137.812	139.781	138.29	0.493	0.954
PTT (sec)	31.219	32.226	31.438	32.903	0.408	0.722
PWB (0-10)	5.8	7.28	6.781	7.774	0.446	0.132
Quick (%)	103.438	93.806	102.312	89.613	0.095	0.664
SBP (mmHg)	127.844	122.156	132.097	127.065	0.993	0.237
TC (mg/dl)	215.694	199.45	192.625	184.452	0.276	0.04
TG (mg/dl)	99.771	90.557	88.438	81.161	0.868	0.341
Thrombocytes (Tsd./µl)	247.594	246.375	246.344	226.603	0.167	0.923
Urea (mg/dl)	26.049	18.23	29.853	20.958	0.508	0.027
Uric acid (mg/dl)	5.288	7.946	4.922	7.361	0.569	0.261
glucose	88.97	76.872	85.656	71.903	0.685	0.108

(mg/dl)						
Resting heart rate (beats/min)	69.469	73.656	67.71	68.194	0.055	0.531
waist (cm)	84.688	80.591	82.848	81.703	0	0.46
weight (kg)	72.355	69.547	73.95	71.189	0.093	0.626